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ABSTRACT 
 
 
 Zolpidem and benzodiazepines (BZs) potentiate the inhibitory action of gamma-
Aminobutyric acid (GABA) by allosterically binding to GABAA receptors (GABAAR). 
Prolonged use of GABAAR positive allosteric modulators (PAM) can lead to behavioral 
tolerance, the diminished response to the same drug dose with repeated use, and 
withdrawal, a group of symptoms that occur due to abrupt end of drug treatment.  
Zolpidem is a short-acting, non-BZ GABAAR PAM whose potential for tolerance and 
withdrawal is unclear. Zolpidem demonstrates sedative efficacy similar to BZs and has 
become a main treatment of insomnia in lieu of BZs. Zolpidem replaced BZs due to 
lower incidences of tolerance and withdrawal after prolonged treatment and 
discontinuation. Despite reported lower incidences, some studies find the occurrence of 
tolerance and withdrawal similar between zolpidem and BZs. Tolerance and withdrawal 
symptoms are likely caused by drug-induced neuroadaptive changes in central nervous 
system (CNS) functioning, and these alterations may be similar between zolpidem and 
BZ. Past rodent research suggests that long term use of zolpidem and BZs may produce 
alterations in normal inhibitory GABAergic and excitatory glutamatergic functioning in 
the cortex, hippocampus, amygdala, and PFC and that these alterations may underlie 
sedative tolerance and withdrawal symptoms.  
 
 The purpose of this project was to examine the molecular mechanisms involved in 
the tolerance cross-tolerance, and withdrawal of zolpidem and diazepam in C57/BL6J 
mice after different treatment durations. Elucidating the mechanisms behind zolpidem 
tolerance and withdrawal is necessary due to the ongoing usage of subunit specific 
GABAAR PAMs and, to a broader extent, an understanding of GABAARs themselves.   
 
 In Study 1, we measured sedative tolerance, cross-tolerance, and GABAAR 
associated mRNA levels in 4 regions of interest (ROI; the cortex, prefrontal cortex 
(PFC), hippocampus, and amygdala) after 3 days of intraperitoneal (i.p.) injections of 
diazepam and zolpidem in comparison to vehicle. We expected that this “short-term” 
exposure duration to diazepam and zolpidem would not result is tolerance, cross-
tolerance, or changes in mRNA levels. Study 2 examined the same measures as in Study 
1, in addition to AMPAR subunits, NDMAR subunits mRNA levels in the ROI, and total, 
surface, and intracellular GABAAR subunits protein expression due to 7 days of 
i.p. injections of diazepam and zolpidem compared to vehicle. Based on previous 
research both groups should become tolerant to zolpidem’s sedative effects and show 
decreases of GABAAR subunits and increases in NMDAR subunits in the ROI. It is also 
expected that there will be decreases in total α1 and γ2 in the cortex, a decrease of surface 
α1 in the cortex, and increases in GluR1 in the hippocampus after zolpidem and diazepam 
treatment. Study 3 measured the same measures as in Study 1 due to 30 days of 
i.p. injections of diazepam and zolpidem compared to vehicle. It was expected that both 
groups would become tolerant to zolpidem’s sedative effects and show decreases of 
GABAAR subunits in the cortex, PFC, and hippocampus. 
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 The development of sedative tolerance and cross-tolerance to the locomotor 
impairing effects (measure of sedation) of zolpidem was measured by activity in the open 
field. Spontaneous withdrawal was also measured by activity and anxiety like behavior in 
the open field. Flumazenil-induced withdrawal was measured by anxiety-like behaviors 
in the elevated plus maze (EPM), activity, and anxiety like behavior in the open field. 
Messenger RNA levels were measured by quantitative real time quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) and protein expression was measured 
by western blot. The surface and intracellular proteins were separated using 
bissulfosuccinimidyl suberate (BS3) cross-linking. 
 
 Three days of diazepam but not zolpidem resulted in cross-tolerance to zolpidem 
in Study 1. Three days of zolpidem but not diazepam resulted in a decrease in the mRNA 
level of the α5 subunit in the hippocampus in Study 1. After 7 days of zolpidem or 
diazepam, mice were tolerant and cross-tolerant to zolpidem’s sedative effects. 
Spontaneous withdrawal resulted in anxiety-like behavior and decreased locomotor 
activity. Flumazenil did induce a robust withdrawal syndrome as measured in the EPM or 
open field. Seven days of zolpidem and diazepam caused significant decreases in the 
mRNA expression of α1, α3, β2, and δ GABAAR subunits in the cortex. Diazepam 
groups had significant decreases in the mRNA expression of α4, β1, γ2 subunits, GAT, 
and gephyrin in the cortex and significant decreases of α5- and β3-GABAAR subunits, 
and the GluN2A subunit in the hippocampus. Seven days of zolpidem resulted in a 
decrease in total α2 subunit protein level and 7 days of diazepam decreased total γ2 
subunit protein levels. Thirty days of diazepam but not zolpidem resulted in cross-
tolerance to zolpidem in Study 3. Thirty days of zolpidem but not diazepam resulted in a 
decrease in the mRNA levels of α1, α2, α3, β1, β2, β3, γ1, and γ2 subunits in the PFC. 
 
 These results suggest that there is a window of time in which sedative tolerance to 
zolpidem is observed. The lack of zolpidem tolerance and minimal mRNA changes due 
to 3 days of zolpidem treatment may be due to its pharmacokinetic profile, zolpidem may 
not be in the system long enough to cause any changes. This may mean that sedative 
tolerance gradually develops and reaches detectable levels at later time points. Sedative 
tolerance and cross-tolerance to zolpidem is in line with other studies, however the 
spontaneous withdrawal is unique. Anxiety- like behavior and decreased activity were 
observed in our studies unlike other studies. The anxiety-like behavior is a common 
symptom of BZ withdrawal however the decrease in activity that was observed is not. It 
is unknown why this occurs though it may be due to a carryover sedative effect or more 
likely a placebo effect. Few studies have examined changes in protein levels. Study 2 
found decreased protein expression of α2 and γ2 in the cortex due to zolpidem and 
diazepam respectively, indicate GABAARs containing those subunits are associated with 
tolerance and cross-tolerance to zolpidem’s sedative effects. This implies that the 
sedative effects of zolpidem is mediated by α1-GABAARs, the development of tolerance 
is mediated by α2-GABAARs due to zolpidem binding to both. There was also a decrease 
in the intracellular α1 subunit which may indicate degradation of an intracellular pool of 
α1 subunits or α1-GABAARs. The lack of zolpidem tolerance due to 30 days of zolpidem 
may be due to increased metabolism displayed as an increase in CYP3A enzymes. It is 
unclear what effect the decrease in GABAAR subunits in the PFC due to 30 days of 
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zolpidem implicate. These may affect tolerance to zolpidem’s other effects such as 
amnesia. 
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CHAPTER 1.    INSOMNIA TREATMENT ISSUES 
 
 
Clinically, the sleep disorder insomnia is defined as difficulty initiating or 
maintaining sleep [1]. Treatment of insomnia is of particular importance because the 
estimated prevalence within the United States (U.S.) adult population is 10% to 30%. 
Insomnia is also often comorbid with the psychiatric disorders anxiety and depression [2, 
3]. Until recently, traditional benzodiazepines (BZs) diazepam, alprazolam, and 
clonazepam were the first-line clinical medications for insomnia. However, the unwanted 
side effects of daytime drowsiness, dizziness, confusion and nausea often resulted from 
BZ use. In addition to unwanted side-effects, long term use of BZs could cause tolerance 
(defined as the need to markedly increase the amount of the substance to achieve the 
desired effect) and withdrawal symptoms (anxiety, insomnia, and seizures that develop 
after cessation of long term BZ treatment) [4, 5]. Tolerance and withdrawal are 
commonly associated with dependence (a desire often strong, sometimes overpowering to 
take psychoactive drugs) and addiction (a compulsive drive to take rewarding stimuli 
regardless of risk) [1, 4, 6-8]. Dependence and withdrawal are serious issues that can 
impede the treatment of insomnia and research into safer alternatives has been ongoing. 
 
Over the past decade, the imidazopyridine zolpidem (brand name Ambien) has 
replaced BZs as the most commonly prescribed drug for patients suffering from insomnia 
in the U.S. Both zolpidem and BZs enhance the actions of the inhibitory neurotransmitter 
gamma-aminobutyric acid (GABA) at GABAA receptors (GABAARs). BZs exhibit non-
preferential binding to α1-, α2-, α3, and α5-containing GABAARs (α1-, α2-, α3-, and α5-
GABAARs). Zolpidem, however, exhibits preferential binding and efficacy at α1-
GABAARs alone and produces therapeutic sedative effects. Zolpidem is purportedly safer 
and has fewer side effects than traditionally used BZs when used properly. However, 
recent studies have shown that zolpidem may be more similar to BZs in terms of 
behavioral tolerance, withdrawal, abuse potential, and physical dependence liability. In 
fact, the frequency of zolpidem abuse and dependence is similar to that of BZs within the 
population that has a prior history of BZ and alcohol abuse.  
 
There has been conflicting evidence concerning zolpidem's ability to induce 
behavioral tolerance and withdrawal in animal models after various treatment doses and 
durations. Also unclear is the degree to which repeated administration of zolpidem can 
produce neuroadaptive changes in GABAergic and glutamatergic function that may 
underlie tolerance and withdrawal. Initial rodent studies indicated little evidence of 
sedative tolerance to zolpidem, however more recent studies present evidence that 
tolerance can develop to zolpidem’s sedative effects. It is known that diazepam tolerance 
and withdrawal can been detected as early as 1 day and as late as 30 days. It is 
hypothesized that BZ tolerance and withdrawal may be caused by overlapping 
neuroadaptive changes. The purpose of this project is to examine tolerance, cross-
tolerance, withdrawal, and molecular alterations in zolpidem and diazepam-treated 
C57/BL6J mice. Elucidating evidence of tolerance, withdrawal, and neuroadaptive 
changes after repeated zolpidem use is necessary due to the ongoing usage of subunit 
specific GABAAR positive allosteric modulators (PAMs) like zolpidem and, to a broader 
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extent, an understanding of GABAARs. Furthermore, given the use of genetically 
engineered animal models for understanding GABAAR function, knowledge about the 
mechanisms underlying tolerance in common background strains will be helpful in 
interpreting knockout and transgenic mouse studies that attempt to identify genetic 
factors that can play a role in drug abuse susceptibility. 
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CHAPTER 2.    LITERATURE REVIEW* 
 
 
History of Hypnotics 
 
The earliest known sedative-hypnotics (drugs used to induce or maintain sleep) 
were alcohol and opium. In the 17th century, the combination of opium and alcohol was 
packaged by the name laudanum for the treatment of insomnia and other medical 
conditions. Laudanum was discontinued due to high incidences of dependence, addiction, 
and death [9]. Other drugs would be developed to treat insomnia. Of those treatments 
barbiturates were of prominent use. Barbiturates were developed in the late 1800s and 
used throughout the 1950s. The first barbiturates were synthesized in 1864 by Adolph 
Von Baeyer and refined by Edouard Grimaux [10]. The first barbiturate approved for 
clinical use was diethyl-barbituric acid, known by barbital. Barbital was synthesized in 
1881 by Max Conrad and M. Guthzeit and marketed to consumers as a sedative-hypnotic 
in 1904 [10]. After barbital, over 2500 agents based on barbital were created, including 
phenobarbital, occasionally used to treat insomnia to this day. The use of barbiturates as 
sedative-hypnotics peaked in the 1930s and 1940s, but usage declined due to high 
occurrences of addiction and death by overdose. 
 
BZs replaced barbiturates as hypnotics because of their lower incidences of 
addiction and overdose compared to barbiturates. The safer alternatives to barbiturates, 
BZs were created by Dr. Leo Sternbach in the 1930s’. The first BZ, Ro 5-0690 or 
chlordiazepoxide (CDP), had hypnotic, sedative, and anticonvulsant effects. CDP was 
marketed for anxiety in 1960 followed by diazepam, marketed for multiple uses including 
the treatment for insomnia in 1963. As more BZs were developed, research into BZ 
function found that BZs are positive modulators of GABAA receptors (GABAARs) like 
barbiturates and bind to ω1 (α1-containing) and ω2 (α2-, α3-, α5-containing) GABAARS 
[11, 12]. It was thought that preferential binding to this site made BZs safer and resulted 
in the absence of the abuse and addiction patients developed with barbiturates. 
 
Unfortunately BZs displayed the same propensity for dependence and addiction as 
barbiturates [5, 13, 14]. Long term BZ use in humans, defined as greater than one year, 
could induce tolerance and withdrawal symptoms. The development of tolerance and 
withdrawal symptoms are more likely to occur in patients with a history of previous BZ, 
opioid, or ethanol abuse and patients with anxiety or depression [15]. The development of 
safer alternatives that have low to no incidences of tolerance and withdrawal effects have 
been ongoing and have led to the recent development of sedative-hypnotic non-BZs that 
should have a reduced capacity for tolerance.  
 
 
------------------------------------ 
* Modified with permission. Wright, B.T., C.F. Gluszek, and S.A. Heldt, The effects of repeated 
zolpidem treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile 
expression in mice: comparison with diazepam. Psychopharmacology (Berl), 2014. 231(15): p. 
2967-79 [16]. 
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Zolpidem as an Alternative 
 
The ongoing issue of dependence to sedative-hypnotics (e.g. barbiturate and BZs) 
has motivated research into safer alternatives. These alternatives include zolpidem, 
zopiclone, zaleplon, and eszopiclone, non-BZs of distinct structural, pharmacokinetic and 
pharmacodynamic properties. Zolpidem was synthesized in 1978 by Jean-Pierre Kaplan 
and George Pascal at Synthélabo Laboratories and patented in the U.S. in 1983. The 
pharmaceutical company Sanofi marketed zolpidem as a sleep aid in the European market 
in 1988 and the U.S. market in 1992. Compared to BZs, zolpidem is thought to be a 
superior sedative-hypnotic due to its preferential binding and efficacy of GABAARs 
containing the α1 subunit (α1-GABAAR) and lower affinity to GABAARs containing α2, 
α3, and α5 subunits. In contrast, BZs have similar binding and efficacy at α1-, α2-, α3-, 
and α5-GABAARs [17, 18]. Zolpidem’s unique pharmacology results in fast acting 
sedative-hypnotic effects that are therapeutically advantageous for inducing sleep [4]. 
Past research has revealed that positive modulation of α1-GABAARs induces sedation, 
sleep, amnesia, and anticonvulsant effects [18, 19]. Zolpidem is currently one of the most 
widely used sedative-hypnotics in the U.S., and under the brand name Ambien©, has 
become a popular sedative-hypnotic with yearly sales of more than 2 billion dollars in the 
U.S. [20, 21]. However some studies suggest the propensity for tolerance and withdrawal 
symptoms to zolpidem is similar to BZs [22, 23]. 
 
 
Limits to Current Alternatives 
 
The preferential affinity and binding of zolpidem to α1-GABAARs was believed 
to decrease the development of tolerance and withdrawal symptoms produced by long 
term use. To date, there have been conflicting evidence of development of tolerance and 
withdrawal to zolpidem- in both human and rodent studies [24-27]. Early evidence in 
rodents suggested that chronic zolpidem administration at relatively high dose levels (e.g. 
60 mg/kg) does not induce tolerance [24]. However, recent studies suggest lower dose 
levels of zolpidem (e.g. 1.25-10 mg/kg) in rodents can induce tolerance [24, 28, 29]. 
Compared to humans, clinical studies do not find evidence of tolerance and withdrawal at 
clinical dose levels (e.g. 5-10 mg/kg), but case studies do find evidence of tolerance and 
withdrawal in humans at large dose levels (e.g.200 mg/kg) of zolpidem [27, 30]. Thus, 
numerous studies have focused on how zolpidem, BZs, other GABAAR modulators affect 
GABAergic transmission might lead to tolerance and withdrawal. 
 
 
Introduction to Zolpidem 
 
Under the brand name Ambien©, zolpidem has largely replaced BZs for the 
treatment of insomnia [20]. The chemical name for zolpidem is N, N, 6-trimethyl-2-(4-
methylphenyl) imidazo [1, 2-a] pyridine-3-acetamide hemitartrate and is an 
imidazopyridine, structurally distinct from BZs (Figure 2-1) [31, 32]. Zolpidem is widely 
available in most countries and known commercially by many names (Ambien©, 
Intermezzo©, Stilnox©, and Zonadin©). Zolpidem is defined by the Drug Enforcement  
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Figure 2-1. Comparison of zolpidem and diazepam structures 
Diazepam as a BZ is a two ring heterocyclic compound with a benzene ring fused to a 
diazepine ring, whereas zolpidem is an imidazopyridine which have an imidazole ring 
fused to a pyridine ring. Modified with permission. Drover, D.R., Comparative 
pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, 
zolpidem and zopiclone. Clin Pharmacokinet, 2004. 43(4): p. 227-38. and Richards, J.G. 
and Martin, J.R., Binding profiles and physical dependence liabilities of selected 
benzodiazepine receptor ligands. Brain Research Bulletin. 45(4): p.381-387 [31, 32].  
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Administration (DEA) as a schedule IV drug (a drug with low potential and risk of abuse 
and dependence). The hemitartrate salt form of zolpidem is commonly taken as a solid 
pill and is commonly ingested orally, but can be administered intravenously (i.v.). 
Pharmacological studies indicate that zolpidem has different pharmacokinetic and 
pharmacodynamics properties than BZs that contribute to its efficacy as a sedative-
hypnotic. 
 
 
Pharmacokinetics 
 
 
Preclinical Studies 
 
Pharmacokinetics describes the absorption, distribution, metabolism, and 
elimination of a drug from the body. The pharmacokinetics of a drug determines the 
onset, duration, and intensity of a drug’s effect. In rodents, a 5-10 mg dose of zolpidem 
has a peak concentration (Cmax) of about 2341 ng/ml and a time of peak concentration 
(Tmax) of 5-15 min [33]. Zolpidem has a volume of distribution (Vd) of 104.9 ml, no 
active metabolites, and has a half-life (t1/2) of approximately 20-90 min [33-35]. In 
rodents, a 5-20 mg dose of diazepam has a Cmax of about 297 ng/ml and a Tmax of 72 min 
[36]. Diazepam has a Vd of 920 ml and a t½ of 52 minutes [37]. Diazepam has an active 
metabolite, desmethyldiazepam, whose half-life is 11.1 hours and has sedative effects 
[37]. In rodents, zolpidem has a higher peak concentration and reaches it in a shorter 
amount of time compared to diazepam. Zolpidem also has a lower volume of distribution 
and a lower t½ than diazepam. In contrast to diazepam, the degradation of zolpidem does 
not lead to the accumulation of active metabolites that can sustain drug action [31, 33, 38, 
39]. 
 
 
Clinical Studies 
 
In humans, a 10 mg dose of zolpidem or diazepam initiates sleep [40-42]. A 10 
mg dose of zolpidem has a Tmax between 1.2-1.6 hours similar. A 10 mg dose of 
diazepam has a Tmax between 1.3-1.4 hours, similar to zolpidem. Zolpidem has a Cmax of 
120-140 ng/ml while diazepam at the same dose has a Cmax of 253-885 ng/ml [31, 43-45]. 
Zolpidem has a bioavailability (fraction of unchanged drug that reaches the systemic 
circulation) of about 70% after first pass hepatic metabolism with 92% bound to protein 
[31]. Diazepam has a bioavailability of about 100% with around 97% bound to protein 
[31, 43, 46]. 
 
The main cytochrome P450 (CYP450) enzyme, isozymes responsible for the 
biotransformation of drugs, that metabolize zolpidem into inactive metabolites is 
CYP3A4 accounting for about 60% of clearance, the amount of drug removed from the 
body per unit time [47]. The other CYP450s that metabolize zolpidem are CYP2C9, 
accounting for 22%; CYP1A2, accounting for 14%; and CYP2D6/CYP2C19, accounting 
for < 3% of clearance [47]. Diazepam is metabolized by CYP2C9, 2C19, 2B6, 3A4, 3A5, 
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3A4 and 2C19 into three active metabolites, desmethyldiazepam, temazepam, and 
oxazepam [31, 43, 44]. Zolpidem has an t1/2 of about 3 hours in comparison to diazepam 
with a long t1/2 (~100 hours due to active metabolites) [48]. Zolpidem has a lower 
bioavailability and a shorter t1/2 than diazepam. In comparison to diazepam’s many active 
metabolites, zolpidem does not have active metabolites.  
 
Recent evidence suggest that gender and age influences the pharmacokinetics of 
zolpidem. There is evidence that women have a lower rate of clearance of zolpidem and 
have higher blood plasma concentrations of zolpidem than men [49-51]. This may be due 
to a tempering effect of testosterone as elderly men also have a lower clearance that is 
correlated with reduced testosterone (a CYP3A4 substrate) in men [52]. These finding 
prompted the U.S. Food and Drug Administration (FDA) to recommend lowering the 
dose of zolpidem for women, as the dose for the elderly was already reduced [53] 
 
 
Pharmacodynamics 
 
 
Preclinical Studies 
 
Pharmacodynamics is the study of the biochemical and physiological effects of 
drugs on the body and the relationship between drug concentration and effect. These 
effects include receptor affinity, receptor efficacy, and drug effect on behavior. 
 
At clinical doses (5-10 mg), zolpidem has preferential affinity for α1-GABAARs, 
lower affinity for α2- and α3-GABAARs, and no affinity for α5-GABAARs [34, 54]. It 
has been shown that increasing the concentration of zolpidem does cause affinity to shift 
towards α2- and α3-GABAARs [55, 56]. Diazepam (10-20 mg) in comparison, has similar 
affinity at α1-, α2-, α3-, and α5-GABAARs [57]. Multiple in-vitro and in-vivo studies 
have discerned the effects of both drugs on GABAAR functioning. The amount of 
zolpidem required to potentiate α1-GABAARs is lower than to potentiate α2-, α3-, and 
α5-GABAARs [17, 57-60]. Zolpidem at high doses (> 10 nM) enhances the amplitude of 
miniature inhibitory post-synaptic currents (mIPSCs), beta wave frequency (low 
amplitude beta waves associated with increased brain activity), and mIPSC duration in 
the cortex [61, 62]. At low doses (< 10 nM), zolpidem decreases the beta wave frequency 
[62]. Diazepam at concentrations of 10 nM-1 μM potentiated Cl- currents and enhanced 
IPSCs in HEK cells, the hippocampus, and the basolateral amygdala (BLA) and central 
amygdala (CeA) [63-65]. 
 
The activation or positive modulation of GABAARs generally depresses motor 
behavior. Zolpidem and diazepam at doses of 1-100mg/kg cause reductions in measures 
of locomotor activity, ataxia, muscle relaxant properties, and loss of righting reflex 
(LORR) [66-72]. In addition to depressing motor behavior, zolpidem and diazepam 
increases the threshold of pentylenetetrazole, electroconvulsive, and isoniazid induced 
convulsions [69, 70]. Zolpidem and diazepam’s effects on sleep structure and associated 
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behaviors show some similarities, both increase slow wave sleep (SWS) and decrease 
body temperature in rodents, though diazepam causes tachycardia and hypertension [73].  
 
Knockout (KO) mice are mice that are missing a particular GABAAR subunit. KO 
mice have been used to discover how different GABAAR subtypes modulate behaviors 
like sedation and hypnosis. KO mice that have the α1 subunit deleted, show a reduced 
hypnotic effect compared to wild-type (no deletion of α1 subunit) counterparts when 
given zolpidem though they show increased hypnotic effect when given diazepam [18]. 
The α1-GABAARs mainly mediate zolpidem’s hypnotic effects while α2-GABAARs are 
responsible for diazepam’s hypnotic effects [18, 74]. However an issue with KO mice is 
that results gained from them may be due to compensatory increases in other GABAARs. 
Another tool used to examine how different GABAAR subtypes modulate behavior are 
point mutation mice. The mice have a single point mutation in the α1-subunit protein, 
allowing for the receptor to be BZ and zolpidem-insensitive. Another benefit is that 
unlike KO mice, there are no compensatory increases in α2, α3-, α5-GABAARs that may 
account for potential effects. Through the use of point mutation mice it has been found 
that α1-GABAARs mediate the locomotor impairing effect (measure of sedation) and 
anticonvulsant effects of zolpidem and the locomotor impairing effects of diazepam [71]. 
This indicates α1-GABAARs mediate zolpidem’s sedative and hypnotic effects and 
partially mediate diazepam’s sedative effects as well [71]. Since α1-GABAARs 
modulation is important for sedation and hypnosis, it is possible that it also plays a part in 
the development of tolerance and withdrawal to these behaviors.  
 
 
Clinical Studies 
 
As in rodents, zolpidem has a greater binding affinity for α1-GABAARs [75, 76]. 
Diazepam shows equal affinity for α1-, α2-, α3-, and α5-GABAARs with human 
recombinant GABAARs [17, 77, 78]. Both diazepam and zolpidem positively modulate 
α1-, α2-, and α3-GABAARs with maximum potentiation > 70% [78]. Zolpidem has a 
GABAAR occupancy in humans of about 27% in the neocortex indicating that zolpidem 
is effective at low occupancy [75].  
 
Zolpidem at clinical doses (5 and 10 mg) exerts a hypnotic effect by shortening 
the latency to sleep, maintaining non-rapid eye movement (NREM) sleep, and increasing 
sleep duration in humans [31, 79]. Zolpidem is highly effective in initiating sleep, but is 
not as effective in maintaining sleep. In humans zolpidem induces sedation, impairs 
memory and psychomotor performance [49, 50, 80, 81]. Zolpidem seems to have 
increased adverse effects when compared to hypnotic alternatives like zaleplon, but lower 
adverse effects than diazepam [80, 82]. Although zolpidem is mainly used as a hypnotic, 
it also has weak anxiolytic, anticonvulsant, and amnesic effects. In humans zolpidem has 
weak anticonvulsant activity against pentylenetetrazole (PTZ) and electroshock 
convulsions in a dose dependent manner [69]. Intraseptal injections of zolpidem impairs 
spatial working memory and induces retrograde memory deficits [83]. Acute zolpidem 
injections also impair associative and contextual memory [84-86]. Diazepam but not 
zolpidem increases inhibition in the human motor cortex despite sedation by both drugs 
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as measured by short interval intracortical inhibition (SICI; a GABAAR mediated 
inhibition in the motor cortex) [87].  
 
 
GABAAR Overview 
 
 
GABAergic System 
 
GABA is the main inhibitory neurotransmitter of the CNS. GABA binds to two 
different types of receptors, GABAARs and GABABRs. GABAARs are ligand gated 
chloride (Cl-) ion channels (transmembrane channels that facilitate the passage of ions 
through a membrane when a ligand binds to the receptor) and GABABRs are 
metabotropic receptors (a receptor that acts through secondary messengers). The 
GABAAR (Figure 2-2) facilitates the passage of Cl
- ions, hyperpolarizing neuron [88-
91]. The GABAAR is heteropentameric (a receptor made up of five subunits) with 19 
known subunits. The subunits, α1-6, β1-3, γ1-3, ρ1-3, δ ,ε, θ, and π, can occupy the five 
positions of the GABAAR [88]. The GABAAR is commonly composed of two α subunits, 
two β subunits, and a γ subunit. GABAARs composed of two α1 subunits, two β2 
subunits, and a γ2 subunit represent about 60% of the GABAARs in the rodent brain and 
are widely expressed in the brain [90, 92-94].. 
 
 
GABAAR Subunit Localization and Distribution 
 
The α1-, α2-, and α3-GABAARs are often located directly opposite the 
presynaptic terminal and are referred to as synaptic receptors based on this localization. 
Synaptic GABAARs modulate phasic (transient/fast) inhibition (< 500 µsecs) in the 
presence of high concentrations (> 50 uM) of GABA released into the synapse. The α4-, 
α5, and α6-GABAARs are mostly located outside the synapse and are referred to as extra-
synaptic receptors based on this localization. Extra-synaptic GABAARs modulate tonic 
(persistent/slow) inhibition (> 500 µsecs) in the presence of low concentrations (< 50 
uM) of GABA that diffuse outside the synapse (Figure 2-3) [92, 95].  
 
The distribution of GABAAR subunit mRNAs and proteins vary from region to 
region in the mouse brain (Figure 2-4) [50, 96, 97]. The distribution of GABAAR 
subunits in the mouse brain show that the cortex and hippocampus contain most of the 
subunits with the exception of α6 and γ1 [93]. The amygdala contains a majority of the 
subunits with the exception of α6 [93]. The cortex has high levels of α1, α2, α3, β2, β3, 
and γ2 subunits. The hippocampus has high levels of α1, and β2 subunits, and very high 
levels of α2, α5, β3, and γ2 subunits. The amygdala has high levels of α2, α3, β3, and γ2 
subunits with high levels of the α1-subunit mRNA expression in the BLA [94]. 
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Figure 2-2. Example of a typical GABAAR complex 
The GABA
A
R is an ion channel that allows for entry of the Cl ion composed of 5 
subunits. GABA
A
Rs are usually composed of 2α subunits, 2β subunits and a γ subunit 
with the interface between α and β subunits contain a GABA binding site and the 
interface of α and γ subunits contains the BZ/non-BZ binding site. Reprinted with 
permission. Jacob, T.C., S.J. Moss, and R. Jurd, GABA(A) receptor trafficking and its role 
in the dynamic modulation of neuronal inhibition. Nat Rev Neurosci, 2008. 9(5): p. 331-
43 [91]. 
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Figure 2-3. Example of the localization of synaptic and extrasynaptic GABAAR 
opposite the presynaptic cleft 
At the GABAergic synapse presynaptic vesicles release GABA onto synaptic and 
extrasynaptic GABAA receptors. Reprinted with permission Rudolph, U. and F. 
Knoflach, Beyond classical benzodiazepines: novel therapeutic potential of GABAA 
receptor subtypes. Nat Rev Drug Discov, 2011. 10(9): p. 685-97 [90]. 
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Figure 2-4. Example of differential regional distribution of α subunits proteins in 
rat brain sensitive to BZs 
The α1 subunit is expressed in most brain regions with high expression in the cortex. The 
α2 subunit has high expression in the hippocampus and amygdala. The α3 subunit has 
high expression in the amygdala, brain stem, basal forebrain and the thalamus. The α5 
subunit is mainly expressed in the hippocampus. Reprinted with permission. Rudolph, U., 
F. Crestani, and H. Mohler, GABA(A) receptor subtypes: dissecting their 
pharmacological functions. Trends Pharmacol Sci, 2001. 22(4): p. 188-94 [97]. 
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GABAAR Subtypes and Modulatory Effects 
 
GABAARs subtypes modulate various behaviors. The positive modulation of α1-
GABAARs mainly cause sedation, hypnosis, partial anticonvulsant effects, anterograde 
amnesia and addiction [71, 90, 98]. The α2- and α3-GABAARs mainly mediate anxiety 
and myorelaxation [98]. Most BZs bind to α1-, α2-, α3-, and α5-GABAARs, while 
zolpidem binds preferentially to α1- GABAARs, has some affinity for the α2- and α3-
GABAARs, and no affinity to the α5-GABAARs [99].  
 
 
Contributions of GABA and Glutamate mRNA and Protein Alterations in the 
Cortex, PFC, Hippocampus, and Amygdala to Sedative Tolerance and Withdrawal 
Symptoms 
 
Although it is known that both BZ and zolpidem can induce tolerance in mice, it 
is unclear whether specific alterations in brain regions mediate tolerance because the 
alterations after repeated BZ and zolpidem on brain regions are inconsistent. While BZs 
and zolpidem affect many brain regions, this project is focusing on the cortex, which 
modulates locomotion as well as the PFC, hippocampus, and amygdala. As stated above 
the cortex, hippocampus, amygdala, and PFC have high expressions of BZ-sensitive 
GABAARs which may play a role in tolerance and withdrawal, particularly withdrawal-
induced anxiety [87, 94, 100, 101]. Symptoms of tolerance and withdrawal have also 
been associated with changes in glutamatergic receptor systems [102-104]. At present, 
there are few studies that measure the effects of repeated zolpidem on GABAAR and 
glutamatergic receptors, however studies that have examined the effects of repeated BZ 
can shed light on the potential changes after zolpidem use.  
 
There are inconsistencies in the changes caused by BZs and zolpidem treatment. 
One consistent finding is that repeated BZ and zolpidem reduced the expression of α1 
GABAAR subunit mRNA and protein and increased the expression of α4 GABAAR 
subunit mRNA and protein in the cortex, although some studies do not see these changes 
[105-114]. However some studies have found that in the rat cortex after diazepam 
treatment (7 and 14 days) there were no significant differences in α1-subunit mRNA, but 
increases in α3-, α4-, and α5-subunit mRNA [107, 111, 115, 116]. There were no changes 
in the β2-subunit but there was a decrease in γ2- subunit mRNA in the cortex [111]. 
Repeated BZ and zolpidem also reduce α1 mRNA and protein expression in the PFC 
[105]. Diazepam treatment caused an increase in the α5-subunit in the PFC [105]. In the 
hippocampus, repeated diazepam has caused a decrease in in α1- and α5-subunit mRNA 
[105, 107, 113, 116]. In the cortex, diazepam withdrawal also reportedly caused an 
increase in GluR1, GluN1, and GluN2B subunit mRNA [104, 117]. In the hippocampus, 
BZ withdrawal induced increases in GluR1, GluN1, and GluN2B subunit mRNA and 
protein and increased AMPAR responses [102, 118, 119]. In addition, diazepam 
withdrawal caused a decrease in GluR1 and GluR2 subunit mRNA expression in the 
amygdala [53, 117].  
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The changes found in all of the regions reflect an imbalance in the excitatory and 
inhibitory tone. A reduction of BZ-sensitive GABAARs seem to be more related to the 
development of tolerance, while the upregulation of AMPARs and NMDARs in these 
regions appear to be more associated with withdrawal induced regulation. 
 
 
Adverse Consequences of Zolpidem Use 
 
 
Tolerance 
 
 
 Preclinical Studies. BZs are known to induce dependence in rodents and 
primates [120]. In rodent and primate models dependence is usually manifested as 
tolerance and withdrawal. As defined in the Diagnostic and Statistical Manual of Mental 
Disorders, 5th Edition (DSM-V), tolerance is operationally defined as a loss of efficacy to 
a given effect at a given dose or the need for higher doses for the same effect [1]. 
Tolerance due to chronic BZ treatment is well documented in rodents [109, 112, 120-
131]. A main BZ that is used to investigate sedative tolerance is diazepam. Chronic 
diazepam treatment results in a robust display of sedative tolerance presented as 
decreased sensitivity to its own locomotor-impairing effects [119, 123, 124, 132]. 
However, there is conflicting evidence concerning the development of tolerance to 
chronic zolpidem in mice, with more evidence of dependence occurring in primates [24, 
38, 133]. The variability in the development of tolerance may be affected by the type of 
behavior measured [28, 112]. Earlier rodent studies found that tolerance did not develop 
to zolpidem’s sedative effects [24]. Some rodent studies do not show that zolpidem can 
cause tolerance to the anticonvulsant and motor-sedative effects while others show 
tolerance to the ataxic and hypothermic effects [29, 38]. Recent studies show that 
tolerance to zolpidem’s sedative effects can occur [25, 105]. In addition to tolerance to its 
own effects zolpidem shows cross-tolerance, development of tolerance to a drug that 
causes tolerance to develop to another drug, to other BZs. It has been found that mice 
previously treated with 28 days of zolpidem were tolerant to the effects of diazepam’s 
hypothermic effect, with partial tolerance to the anxiolytic effect, and no tolerance to the 
sedative effect [112]. Zolpidem had a decreased potency to induce locomotor impairment 
and antagonize isoniazid-induced convulsions in mice treated with 10 days of midazolam 
[24]. 
 
 
 Clinical Studies. In human and non-human primates chronic, use of zolpidem has 
been shown to lead to dependence accompanied by withdrawal, though there are some 
studies that find zolpidem maintains a low abuse potential in humans [26, 134-138]. 
Many human case studies show common themes between the patients that abuse 
zolpidem. These themes are tolerance and withdrawal (Table 2-1) [26, 139, 140].  
 
 Patients who become dependent on zolpidem tend to use zolpidem at 
supratherapeutic doses (> 20 mg); though there are those who maintain dependence 
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Table 2-1. Case reports on dependence/abuse of zolpidem 
 
 
M = male, F = female; nr = not reported. aConcomitant abuse of zopiclone and zolpidem. 
b10–40 quaque hora somni (qhs; every hour of sleep).  
The use of doses outside the therapeutic range (> 10mg/kg), increase in dose over time, 
tolerance, withdrawal, as well as usage during the daytime are common in those who 
abuse zolpidem. Reprinteda nd modified with permission. Hajak, G., et al., Abuse and 
dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a 
review of case reports and epidemiological data. Addiction, 2003. 98(10): p. 1371-8 
[26]. 
 
 
  
No. 
Age 
(years) 
Gender 
Highest daily 
dose (mg/day) 
Daytim-
e Intake 
Dose 
increase 
Tolerance 
Withdrawal 
symptoms 
Former 
dependence 
Psychiatric 
complicati-
ons 
Reference 
 1 67 F 100 + + + + + + Madrak & Rosenberg 2001 
 2 43 F 450–600 – + + + – nr Aragona 2000 
 3 39 M 120–480b nr + nr + – + Golden & Vagnoni 2000 
 4 42 F 300 nr + + + + + Vartzpopulos et al. 2000 
 5 30 F 400–500 nr + + + + + Vartzpopulos et al. 2000 
 6 26 F 160–200 nr + + + + + Vartzpopulos et al. 2000 
 7 33 M 120 nr + + + + + Vartzpopulos et al. 2000 
 8 45 F 
40 
(+zopiclone) 
+ + + + – + Harter 1999
a
 
 9 49 M 50–80 + + + + – – Ströhle 1999 
10 50 F = 600 + + + + + + Hofmann & Eichmann 1998 
11 44 F 30–300 + + + + nr + Sakkas 1999 
12 63 F 300 + + + + nr ? Courtet 1999 
13 28 F 800 – + – + nr ? Courtet 1999 
14 69 F 200 + + + – nr ? Courtet 1999 
15 32 M 60 + + + – + ? Courtet 1999 
16 45 M 120 + + + + nr ? Courtet 1999 
17 40 M 200 + + nr nr + ? Courtet 1999 
18 35 M 100 + + nr nr nr ? Courtet 1999 
19 55 F = 200 nr + + + nr + Ravishankar 1998 
20 28 M = 100 nr + nr + nr + Ravishankar 1998 
21 53 M 140 + + + + + – Bottlender 1997 
22 37 M 130 + + + + – – Gilbert & Stats 1997 
23 35 M 200–300 – + + + – + Chamorro-Garcia 1996 
24 33 M 300–400 + + + + – nr Sanchez 1996 
25 75 M 70 + + + + – nr Thome 1995 
26 33 M 150–280 + + + + – + Gericke 1994 
27 42 F nr nr nr nr + + + Bruun 1993 
28 52 M 60–70 nr + + + + + Bruun 1993 
29 55 F = 120 + + + + + nr Bruun 1993 
30 60 F 100 nr + + + + + Cavallaro 1993 
31 31 F 70–80 + + + + nr nr Cavallaro 1993 
32 67 F 100 nr + + + – + Göder et al. 2001 
33 50 F 450 + + nr + – nr 
Barrero-Hernandez et al. 
2002 
34 51 M 1200 + + nr + + nr Correas Lauffer et al. 2002 
35 46 F 200 nr + nr + + + Correas Lauffer et al. 2002 
36 40 F 200 + + nr + + + Correas Lauffer et al. 2002 
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below this dose) [26, 135, 141]. Another common theme are that those who become 
dependent previously abused BZs, opioid, and alcohol, or had psychiatric disorders [26]. 
Though some studies looking at extended use of zolpidem do not find escalation or 
tolerance to zolpidem’s sedative effects in insomniacs and “normal” patients [40]. 
 
 
Withdrawal 
 
 
 Preclinical Studies. As defined in the DSM-V, withdrawal is the typical effects 
associated with the sudden stoppage of a drug[1]. For BZs and zolpidem the withdrawal 
syndrome is displayed as hyper-excited activity, like increased anxiety and insomnia and 
in severe cases seizures and hallucinations. Tolerance and withdrawal tend to be 
associated with each other, but they do not always occur together. Tolerance and 
withdrawal may have similar mechanisms. Withdrawal effects in rodents and primates 
can take many forms. Rats given chronic lorazepam experienced spontaneous and 
precipitated withdrawal, measured by motor activity within the home cage and increased 
electromyography (EMG) activity compared to control [38]. Chronic zolpidem compared 
to lorazepam did not display withdrawal symptoms [38]. Increased precipitated 
withdrawal scores (PAS) which include convulsions, motor signs, dyskinesia, autonomic 
signs, and affective signs were seen after chronic diazepam [142]. Mice given chronic 
diazepam and subjected to either repeated withdrawals or a single withdrawal, have a 
lower dose threshold for pentylenetetrazole (PTZ) after flumazenil precipitated 
withdrawal [143]. Many studies have found that BZs induce hyperactivity and anxiety-
like effects in rodents. Of note is the duration between cessation of BZ treatment and the 
development of withdrawal symptoms. Some studies identify symptoms within 24 hours 
of drug termination while others saw symptoms after 96 hours [104]. Other studies have 
found that mice treated with zolpidem do not have clonic seizures when given the β-
carboline inverse agonist FG-7142 after 4 days of treatment [144]. 
 
 
Clinical Studies. Initially zolpidem was thought to be absent of negative effects. 
Emerging case studies have found that patients increase zolpidem dosage beyond clinical 
doses. Once these patients stop taking these high doses, withdrawal occurs. Human 
withdrawal from BZs are well documented and tend to be severe, as dosage increases 
resulting in severe insomnia, seizures, anxiety, sweating, tremors, and irritation [139, 
145, 146]. Patients tend to take supratherapeutic doses of these drugs due to the 
prescribed doses losing efficacy (tolerance) or to prevent withdrawal symptoms [30]. 
 
 
Relationship Between Duration of Zolpidem Use and the Emergence of Tolerance 
and Withdrawal 
 
Most controlled studies investigating the effects of repeated zolpidem use in 
humans have not found tolerance and withdrawal. These studies allowed participants to 
self-administer and did not show an increase in dose level across time, suggesting 
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tolerance to the sedative effects do not occur. The studies also found there were no 
withdrawal effects such as next day insomnia or cognitive dysfunction [27, 40]. These 
data indicate zolpidem is a safe drug with a low propensity for tolerance and withdrawal. 
However, most of these controlled studies were done in healthy adults with or without 
insomnia and with no prior BZ, opioid, or alcohol abuse. Unlike controlled studies, case 
studies have recorded numerous cases of zolpidem dependency primarily in patients with 
prior BZ, opioid, or alcohol abuse and psychiatric disorders. The amount of time it takes 
these patients to become tolerant to zolpidem varies. Usually patients become tolerant 
within 1-6 months of starting zolpidem, increasing the dose substantially from 10 mg to > 
100 mg [147, 148]. The amount of time between cessation of zolpidem and the 
emergence and severity of withdrawal symptoms also varies. In humans mild withdrawal 
symptoms, like anxiety and tremors occurs within hours of the last dose [149]. More 
severe withdrawal symptoms (e.g. seizures and hallucinations) can occur up to 3 days 
after the last dose of zolpidem [139, 145]. It should be noted that these symptoms usually 
occur after cessation of extremely high doses of zolpidem that taken for up to two years.  
 
Along with humans, non-human primates can display tolerance to zolpidem. 
Interestingly primates show tolerance to the sedative effects of zolpidem at relatively low 
doses of 3.2 and 5.6 mg/kg over the course of 7 days of treatment [138]. Non-human 
primates also reliably show withdrawal symptoms after the abrupt end of zolpidem 
treatment. At increasing doses from 1-32 mg/kg, baboons showed withdrawal symptoms 
after abrupt end of zolpidem treatment after 78 days of treatment [6]. Acute flumazenil 
given 35 days after continuous zolpidem self-injections also induced physical symptoms 
typically seen after BZ withdrawal in baboons, including decreased eating, increased 
aggression, tremors, vomiting, and abdominal discomfort [150]. The termination of long-
term zolpidem administration (> 60 days) also caused spontaneous withdrawal symptoms 
comparable to BZs and barbiturates [133, 150]. 
 
In comparison to humans and non-human primates, rodents can become tolerant 
to zolpidem and BZs after shorter treatment durations. Rodents can become tolerant to 
the sedative effects of BZs as early as 1-3 days of treatment at doses of 5-20 mg/kg [122, 
127, 130, 131, 151]. Rodents can also exhibit mild withdrawal symptoms similar to 
humans 1-3 days after cessation of BZs [104, 144]. Some studies show at doses of 5-10 
mg/kg, rodents become tolerant to zolpidem after 7-14 days of repeated zolpidem 
compared to humans after > 1 month at doses greater than 10 mg [25, 29, 105]. However, 
unlike repeated zolpidem use in humans and primates, there are few studies that examine 
zolpidem withdrawal, with only one study reporting withdrawal symptoms after cessation 
of zolpidem [24, 38, 144, 152]. 
 
 
Usefulness of Rodent Models of Sedation and Limitations 
 
Rodent models of sedation are useful tools to understand the neuromechanisms 
underlying sedation in humans. These models are valuable due to the ability to control 
factors that might underlie tolerance in humans. In addition, rapid development of 
tolerance can be achieved in rodents compared to human and primate. As stated above, 
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rodents can become tolerant to zolpidem after 7 days of drug treatment compared to 
humans, which take > 1 month to become tolerant to the effects of zolpidem. While the 
rodent model of sedation may be a useful tool to study zolpidem tolerance, they may be 
limited in detecting withdrawal symptoms due to species differences in the 
pharmacokinetics and pharmacodynamics of zolpidem, in addition to the differential 
distribution of GABAARs in the brain. 
 
 
Abuse, Dependence, and Addiction 
 
 
Preclinical Studies. Few studies evaluate the addictive properties of zolpidem in 
contrast to the many studies evaluating the addictive properties of BZs [153, 154]. The 
primary measure used to evaluate addictive behavior in primates and rodents is self-
administration. Reinforcement studies have found that primates and rodents self-
administer BZs, but not at the rate of abusive drugs like cocaine [155-159]. Due to the 
sedative effects of BZs at higher doses, an inverted U-shaped response curve is seen. The 
U-shaped curve shows that response rates (function of reinforcement) as dose increase 
but there is a downturn in response rate due to the locomotor-impairing effects of higher 
doses.  
 
Unfortunately, it is difficult to discern between physical dependence and 
addiction, as both tend to accompany one another. Physical dependence is characterized 
by the body’s adaption to a given drug while addiction is the compulsive need for a drug. 
It has been found however that dependence can occur without reinforcement [160]. Most 
addictive drugs increase glutamatergic transmission in the mesolimbic dopamine system. 
Dependence and abuse have been behaviorally demonstrated, as baboons self-administer 
zolpidem indicating abuse potential but this has not been found in rodents [133, 138, 150, 
161, 162]. Zolpidem has similar rates of self-injection to barbiturates and cocaine and has 
a higher rate of self-injection than triazolam [138, 162].  
 
Abuse and dependence in mice are related and usually measured after 
discontinuation of drug treatment. In mice intracranial self-stimulation (ICSS) and 
conditioned place preference can be used as measures of a drug’s reinforcing effects. BZs 
and other drugs of abuse reduce the amount of stimulation required for ICSS [163, 164]. 
It has been found that diazepam but not zolpidem dose dependently reduced reward 
threshold for ICSS in C57BL/6J mice [165]. This reward enhancing effect was also found 
in α1(H101R) mice, but not α2(H101R) or α3(H101R) mice, indicating that α2- and α3-
GABAARs play more of a role than α1-GABAARs in the rewarding effects of BZs. 
Conditioned place preference (CPP), a paradigm where rodents develop a preference for 
one of two distinctive compartments that was previously associated with the BZs, has 
also been used to identify the reinforcing effects of BZs, but not zolpidem [161, 166].  
 
Though studies suggests that α1-GABAARs may not mediate rewarding effects in 
rodents, recent studies challenge this view. A single dose of zolpidem and diazepam 
increase firing of mesolimbic dopamine neurons via modulation of α1-GABAARs in the 
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ventral tegmental area (VTA) [167]. Wild-type but not α1 (H101R) mice develop a 
preference for a sucrose solution with midazolam indicating a role of α1-GABAARs in 
the reinforcing effects of BZs [168, 169]. Though there may be a partial role of α1-
GABAARs in the rewarding effects of BZs, there are no studies that show zolpidem alone 
produces these effects in mice. The differences in rewarding effects between rodents and 
primates may be due to the differences in GABAARs subtypes and/or binding 
characteristics [76]. Primate studies raise concerns about the possible rewarding effects of 
zolpidem and the potential for the development of abuse in humans [140]. Drugs with 
positive reinforcing effects have been implicated as causes for abuse and dependence, 
thus more research into the rewarding effects of zolpidem may provide insights into the 
neural mechanisms underlying drug abuse by other drugs acting through GABAARS 
[170]. 
 
 
Clinical Studies. Several agencies state that along with BZs, zolpidem is a highly 
prescribed drug of abuse [171]. In addition, there has been a 136% increase in emergency 
room visits from 2004 and 2011 due to nonmedical usage of zolpidem [172]. According 
to the World Health Organization it is thought that abuse of zolpidem is similar in rate to 
other hypnotic BZs, though some studies report it as significantly lower [26, 134, 135, 
173]. Like hypnotic BZs, there appears to be some propensity for abuse among humans 
and baboons [133, 135-138]. Griffith and Weerts’ review [6] focusing on human over 
usage of BZs found that those who used for more than 4 months tend to fall into two 
categories: recreational users and “quasi-therapeutic” users. Those who used BZs as 
hypnotics tend to make up 23% of BZ users yet account for the majority of sales of 
hypnotics. Such long-term usage may indicate a propensity for abuse that is marked by 
dependence, tolerance, and possibly withdrawal. 
 
Zolpidem’s propensity for abuse has been recorded through case and clinical 
studies. A similar characteristic of those who tend to abuse zolpidem is their prior abuse 
of other BZs and/or opioids [145, 174]. The cases of zolpidem abuse usually contain a 
withdrawal syndrome. This syndrome comes after abrupt ending of zolpidem at doses 
from 20 mg to 2000 mg a day. The sudden disuse of zolpidem at these doses result in 
anxiety, sweating, palpitations, seizures [139, 145, 147]. Drug naïve humans show 
similar potential to abuse to both zolpidem and triazolam, with zolpidem at its highest 
dose (20mg) increasing feelings associated with abuse potential like happy and good 
effects [135]. Another study with drug naïve humans found a similar profile with 
zolpidem at its highest dose (20 mg) increasing feelings associated with abuse, such as 
high, like, and good effects [137]. Most case studies define this abuse of zolpidem as 
dependence not addiction. There is a case in which zolpidem displayed addictive 
properties such as intense craving and drug seeking to the point of harming themselves to 
attain the drug [146, 148]. Along with the negative effects associated with abuse many of 
these studies state that patients abuse zolpidem for stimulation, euphoria, and relaxation 
properties [146, 148, 175]. 
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Side Effects/Toxicology 
 
Like most sedatives zolpidem has side effects that interfere with next day 
performance. Zolpidem in rodents has amnesic effects on a variety of memory tasks like 
passive avoidance (1-2 mg/kg), contextual fear conditioning (1, 3, and 10 mg/kg), and the 
plus maze discriminative avoidance task (PM-DAT) [85, 176, 177]. 
 
There are few incidences of toxicity in humans at therapeutic doses and fewer 
instances of overdose compared to BZs. A review of zolpidem’s side effects found they 
come in the form of lightheadedness, dizziness, somnolence, headache, fatigue, memory 
deficits, nightmares, confusion, and depression, nausea, and vomiting [178-180]. In some 
instances delirium, nightmares, and hallucinations can occur, though these are uncommon 
[181]. The most common side effects appear to be amnesia and parasomnias (sleep 
walking/eating/driving) and in rare occasions attempted para-suicide [180, 182, 183]. 
Zolpidem is also associated with increased major injury due to unintentional falls and 
vehicle incidents [184]. 
 
 
Neuropharmacology and Neurocircuitry of Adverse Effects 
 
 
Modulation of GABAARs 
 
Studies have looked into possible neuroadaptive mechanisms that may account for 
tolerance and withdrawal to BZs and zolpidem, focusing mainly on changes in GABAAR 
subunits in in-vitro and in-vivo assays. Most studies investigate changes after long-term 
BZ treatment, but fewer have looked into the changes that may occur after long-term 
zolpidem treatment [92, 116, 185]. A main finding is that α1 subunit mRNA levels are 
decreased after chronic use and withdrawal from zolpidem and BZs in the cortex [106, 
107, 109, 114]. Zolpidem and diazepam causes decreases in α1 subunit mRNA levels in 
the prefrontal cortex [105]. Also it appears that some studies find decreases in subunits 
that make up α1-GABAARs (β2 and γ2 subunits) and increase subunits the α4 subunit 
[186]. This is in contrast to a study of recombinant α1β2γ2S GABAARs in HEK293 cells, 
finding increases in α1 and γ2S mRNA expression after a 96 hour withdrawal from 
zolpidem [187]. 
 
 There are differences in the time frame these changes occur and also differences 
in if they occur during chronic treatment or during withdrawal [92]. In cerebellar granule 
cells it was found that long term diazepam treatment and withdrawal caused a reduction 
of α1 and both γ2 mRNA [186, 188]. This same study and others found that long term 
diazepam causes an increase in the α4 subunit mRNA and that withdrawal from diazepam 
caused an increase in α4 subunit protein [188, 189]. In the rat cortex after 7 or 14 days of 
diazepam treatment there were no significant differences in amount of α1 subunit mRNA, 
but there were increases in α3, α 4, and α5 subunit mRNA, as well as an increase in the 
α5 subunit in the PFC [105, 111]. There were no changes in the β2 subunit but there was 
a decrease in γ2 subunit mRNA [111]. Alterations in protein expression also occur after 
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BZ and zolpidem treatment and may be concurrent or an effect of the decrease in mRNA 
expression.  
 
Uncoupling is another mechanism by which BZs and zolpidem may induce 
tolerance and possibly withdrawal. Uncoupling is defined as a disassociation of the 
GABA and BZ binding interface. Chronic diazepam and zolpidem caused a decrease in 
the GABA potentiation by [H]flunitrazepam binding (a measure of uncoupling) in rat 
cortical membranes and HEK cells containing recombinant GABAARs [190, 191]. 
Flurazepam also decreases GABA potentiation by [H]flunitrazepam binding [192]. 
Zolpidem treatment also increases [H]flunitrazepam binding sites and increases α1 and γ2 
subunit mRNA alongside inducing uncoupling [191, 193]. Another measure of 
uncoupling is the reduced ability of BZs to enhance GABA induced IPSPs [194, 195].  
Chronic diazepam decreases potentiation by GABA, indicating reduced GABAAR 
function [188]. It appears uncoupling does not involve decreasing GABAARs. It has been 
hypothesized that uncoupling involves altering the expression of α subunits and not 
affecting the amount of GABAARs. Internalization has been thought to mediate this 
change in expression by increasing internalization of the α1 subunit and increasing 
surface expression of α4 after chronic BZ treatment [196-199]. 
 
BZs acting on the reward pathway may play a role in development of dependence. 
Many BZs can induce addiction after long periods of use and some case studies of 
zolpidem find patients experiencing positive effects like euphoria and increased energy. 
There is some conflicting evidence on the role of α1-GABAAR in mediating reward. It 
has been found that α1-GABAARs may mediate dependence and abuse through activating 
the VTA. BZs and zolpidem modulate the VTA through activation of α1-GABAARs on 
local interneurons [168]. The local interneurons no longer inhibit dopaminergic neurons 
in the VTA, allowing for increased firing. Though it has been found that zolpidem does 
not cause reward enhancement and that reward enhancement was not abolished in α1 
point mutation mice (mice with a H101R mutation) making their α1-GABAAR BZ 
binding pocket non-functional [165] 
 
 
Glutamate Receptors 
 
 
NMDA/AMPA. While changes in GABAARs likely play a major role in 
mediating tolerance and withdrawal to BZs and zolpidem, changes in other 
neurotransmitter systems are also likely involved. GABAARs are commonly located on 
excitatory neurons, inhibiting these neurons to maintain optimal excitatory 
neurotransmission. Prolonged GABA inhibition caused by repeated BZ or zolpidem 
treatments may produce compensatory increases in NMDARs, AMPARs, and 
metabotropic glutamate receptors (mGluRs). Increases in these glutamate receptors may 
influence the development of tolerance and withdrawal to zolpidem and BZs. 
 
In support of compensatory increases, the NMDAR antagonist MK-801 has been 
shown to block tolerance and withdrawal to various BZs [126, 200, 201]. Chronic BZs 
  
22 
have been found to increase in-vitro glutamate release and NMDA-stimulated cGMP 
efflux [127, 202]. Chronic use of BZs have been found to increase the mRNA and protein 
levels of NMDAR and AMPAR subunits in the cortex and hippocampus and also 
decrease AMPAR subunits in the amygdala. In rats it has been found that the mRNA and 
protein levels of GluN1 and GluN2B subunits in the dentate gyrus are increased in rats 
tolerant to diazepam 24 hours after last injection [118, 119]. In the CA1 and CA2 regions 
of the hippocampus, there were decreased NMDA-mediated currents as well as decreased 
GluN2B subunit mRNA and protein levels in hippocampal slices [119, 203]. GluN1 and 
GluN2B subunit protein expression has been found to be increased in the rat cerebral 
cortex as well [117].  
 
GluR1 subunit mRNA expression was increased in the frontal cortex and 
hippocampus but the GluN1 subunit mRNA expression was not changed in either region 
during withdrawal 96 hours after diazepam cessation nor while tolerant[104]. In 
hippocampal slices there are also increases in AMPAR function after flurazepam 
withdrawal and increases in GluR1 subunit protein expression [102]. Withdrawal from 
chronic s.c. administration of diazepam caused an increase in AMPARs (increase in [3H] 
Ro48-8487) in the hippocampus and thalamus [53, 201]. Diazepam withdrawal lead to a 
decrease in GluR1 and GluR2 subunit mRNA expression in the amygdala and a decrease 
in GluR1 subunit mRNA expression in the cortex [53, 117]. Most of the studies find that 
AMPAR induced changes in mRNA and protein expression occur during withdrawal. 
AMPAR may have an effect on tolerance as GluR1-/- mice show reduced tolerance to but 
increased withdrawal effects to flurazepam[121]. Based on the previous studies it appears 
that changes in NMDAR and AMPAR expression due to chronic BZ usage primarily 
occur in the hippocampus. 
 
 
Metabotropic Glutamate Receptors. mGlu5 when activated causes intracellular 
calcium (Ca+) to be released allowing for the activation of multiple kinases. mGlu5 has 
been found to be increased after 7 days of zolpidem treatment (30 mg/kg) in mice along 
with downstream proteins like phospholipase Cβ and calcium/calmodulin-dependent 
protein kinase Iiα [204]. mGlu5 is co-localized and co-expressed with the α1-GABAAR 
subunit in the hippocampus [205]. 
 
 
BDNF 
 
It has been found that brain-derived neurotrophic factor (BDNF) may play a role 
in BZ and zolpidem tolerance. Acute triazolam and zolpidem decrease BDNF protein 
levels in the hippocampus [206]. Acute zolpidem causes an increase in association of 
methyl-CpG binding protein 2 (MeCP2) with BDNF promoter IV and an increase in the 
association of phosphorylated cyclic adenosine monophosphate (cAMP) response 
element binding protein (pCREB) with BDNF promoter I, though long-term treatment 
did not affect any of these factors [206]. It is known that BDNF decreases mIPSC. BDNF 
decreases both the surface expression of GABAARs and modulates of mRNA expression. 
BDNF decreases GABAAR surface expression in general and specifically by the 
  
23 
JAK/STAT pathway BDNF downregulates α1-GABAARs by activation of inducible 
cAMP early repressor (ICER) which binds to pCREB to decrease mRNA expression 
[207, 208]. 
 
 
Kinases 
 
The cAMP –dependent protein kinase (PKA) and Ca2+/phospholipid-dependent 
protein kinase (PKC) modulate GABAergic functioning. Both kinases modulate mIPSCs 
in opposing ways in cortex, hippocampus and other brain regions. PKA decreases mIPSC 
amplitudes in pyramidal cells in the hippocampus whereas PKC increases mIPSC peak 
amplitudes in granules cells [209]. PKA activates ICER to regulate α1 subunit mRNA 
expression by preventing the binding of pCREB with the GABRA1 promoter leading to a 
decrease in α1-GABAARs [210]. Chronic zolpidem has been found to increase 
phosphorylated PKCγ in the limbic forebrain [211]. 
 
 
Influence of GABA Transmission on Sleep, Sedation, Motor Inhibition, and 
Reinforcement: Neurocircuitry 
 
 
Sleep/Sedation 
 
Most sedative-hypnotics are positive modulators of GABAARs. Sleep is a 
naturally occurring state of unconsciousness accompanied by altered consciousness, 
reduced reactivity to external stimuli, and reduced voluntary movement, while sedation is 
an artificially induced state where the level of arousal is suppressed [212]. Both states are 
accompanied by decreases in voluntary movements allowing motor activity to be used as 
an index for both behaviors as seen in many studies evaluating BZ hypnotics and 
sedatives [213, 214]. Major regions have been identified that modulate circadian rhythms, 
REM, non-REM sleep, and sleep-homeostasis. The preoptic area appears promote sleep 
as the ventrolateral preoptic area (vLPO) and the median preoptic nucleus (MnPO) 
provide GABAergic inhibitory projections to the basal forebrain and brainstem arousal 
systems. The GABAergic projections to the arousal system inhibit the release of 
histamine, 5-HT, dopamine, acetylcholine, and orexin to various cortical regions. Most of 
these regions with the exception of the LC express α1-, α2-, and α3-GABAARs and are 
subject to zolpidem and diazepam, inducing sedation or sleep (Figure 2-5) [215, 216]. 
While the circuitry of sleep has been well defined this is not the case with sedation 
though there is some evidence sedation works along the same sleep pathway [217]. 
 
There is overlap in the behavioral aspects of sleep and sedation and work done to 
disseminate how modulation of GABAARs affect both. In α1(H101R) and α3(H126R) 
mice diazepam do not affect sleep latency or sleep duration compared to control mice 
[74, 218]. When zolpidem is given to α1(H101R) at a hypnotic dose (same dose used for 
measures of sedation, 5-10mg/kg) non-REM sleep is no different than wild-type 
mice[219]. However diazepam’s and zolpidem’s sedative effect is missing in α1(H101R)  
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Figure 2-5. GABAARs modulated in the arousal system 
GABA
A
Rs are expressed in many regions that regulate arousal and sleep.  
ACh, acetylcholine; ADO, adenosine; DA, dopamine; DpMe, deep mesencephalic 
reticular nucleus; DR, dorsal raphe nucleus; Glu, glutamate; Hcrt, hypocretins ⁄ orexins; 
His, histamine; LC, locus coeruleus; LDTg, laterodorsal tegmental nucleus; MCH, 
melanin concentrating hormone; NA, noradrenaline; n.d., not determined; nRt, reticular 
nucleus of the thalamus; PeF, perifornical nucleus; PH, posterior hypothalamus area; 
PPTg, pedunculopontine tegmental nucleus; SubC, subcoeruleus nucleus; TM, 
tuberomammillary nuclei; VLPAG, ventrolateral periacqueductal gray; VLPO, 
ventrolateral preoptic area; 5-HT, serotonin. Reprinted with permission.Winsky-
Sommerer, R., Role of GABAA receptors in the physiology and pharmacology of sleep. 
Eur J Neurosci, 2009. 29(9): p. 1779-94 [215]. 
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[98, 214]. Due to the effects found in point mutation mice it appears that modulation of 
α1-GABAAR induces sedation while modulation of α2-GABAAR induces sleep. 
 
 
Motor Inhibition 
 
Sedation in mice is usually measured as a decrease in motor activity. Movement is 
in general there is a balancing act between cortical excitation and inhibition from the 
basal ganglia. Excitation and inhibition of locomotor activity is controlled by the MLR 
and pedunculopontine nucleus (PPN) respectively within the mesopontine tegmentum. 
The MLR activates muscle tone through the locus caeruleus (LC), raphe nuclei and 
excitatory reticulospinal system and motion through CPGs. MLR activation is caused by 
activation of cholinergic and glutamatergic receptors. PPN decreases muscle tone 
hyperpolarizing the motoneurons and possibly suppressing CPGs possibly decreasing 
locomotion[220]. The basal ganglia specifically the substantia nigra pars reticulate (SNr) 
GABAergic neurons project to the MLR and PPN providing tonic inhibition and 
modulate locomotion and muscle tone. The basal ganglia receives innervation from the 
cerebral cortex and as stated before sends projections to the spinal cord through the 
mesopontine tegmentum. 
  
The cortical-basal ganglia circuit is a major component of volitional movement. 
Glutamate and GABA control movement through direct and indirect circuits. This direct 
circuit is a loop in that the glutamatergic neocortical neurons projects to the striatum 
which also receives dopaminergic projections onto the D1 receptors both projections 
exciting the striatum. The striatum sends GABA to the internal pallidum inhibiting its 
GABAergic neurons which would send GABA to the thalamus, since the thalamus is no 
longer inhibited by the internal pallidum it then sends glutamate back to the neocortex 
thus initiating movement. Inhibition of movement occurs when the D2 receptors on the 
striatum of activated by dopamine leading to GABA release from the striatum onto the 
internal and external pallidum. The external pallidum would send inhibitory projections 
onto the subthalamic nucleus but due to the inhibition from the striatum does not and this 
allows the subthalamic nucleus to send glutamatergic projections to the internal pallidum 
causing a net excitation. With the internal pallidum activated it sends GABA to the 
thalamus restricting glutamatergic release onto the neocortex [221].  
 
 
Project Purpose 
 
The purpose of this project was to examine tolerance, cross-tolerance, withdrawal, 
and molecular alterations in zolpidem and diazepam-treated C57/BL6J mice after 
different treatment durations. Elucidating the mechanisms behind zolpidem tolerance is 
necessary due to the ongoing use and development of subunit specific GABAAR PAMs 
and the overall understanding of GABAAR mechanisms. We hypothesized that 3 days of 
repeated zolpidem or diazepam would result in no behavioral and molecular alterations. 
We hypothesized that 7 days of zolpidem and diazepam would result in tolerance, cross-
tolerance, withdrawal, and alterations in GABAergic and glutamatergic mRNA and 
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protein levels. We hypothesized that 30 days of zolpidem and diazepam would result in 
tolerance and cross-tolerance to zolpidem’s effects and alter GABAergic mRNA levels. 
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CHAPTER 3.    EXPERIMENTAL METHODS* 
 
 
 The purpose of Study 1 was to determine the effects of 3 days of zolpidem and 
diazepam on the sedative effects of zolpidem treatment and mRNA levels of GABAAR 
subunits and GABAAR associated proteins. The purpose of Study 2 was to determine the 
effects of 7 days of zolpidem and diazepam on the sedative effects of zolpidem treatment, 
spontaneous withdrawal, flumazenil-induced withdrawal, and mRNA levels of GABAAR 
subunits, GABAAR associated proteins, AMPAR subunits, and NMDA subunits. Study 2 
also examined the effect of treatments on total and cell surface expression of GABAAR 
receptor subunits proteins. The purpose of Study 3 was to determine the effects of 30 
days of chronic zolpidem and diazepam on the sedative effects of zolpidem treatment and 
mRNA levels of GABAAR subunits and GABAAR associated proteins.  
 
Studies 1-3 examined sedative tolerance by measuring the locomotor activity of 
mice during open field testing. Locomotor activity was defined as the horizontal distance 
traveled (in cm) during a 60-min open field test. In rodents, decreases in open field 
locomotor activity is a standard behavioral test for assessing the sedative effects of drugs 
[66, 69, 222-226]. Tolerance to drug sedation is commonly observed as the diminished 
effectiveness to reduce locomotor activity [25, 105].  
 
Withdrawal-like symptoms were measured by locomotor activity during open 
field testing and anxiety-like behavior in the elevated plus maze (EPM). In rodents and 
humans, abrupt discontinuation of a sedative can cause hyperactivity and anxiety-like 
effects [53, 121, 227]. Hyperactivity was characterized as increased distance traveled in 
the open field. The Open-field anxiety-like behaviors were identified by the decreases in 
the percent of time and entries into the center zone and a decrease in frequency with 
which the mice stood on their hind legs in the maze (frequency of vertical activity or 
rearing) [17]. Anxiety-like behaviors in the EPM were identified as decreases in the 
percent of entries or time in the open arms [228-231].Tolerance and withdrawal from BZs 
and zolpidem are also associated with alterations in mRNA expression. Messenger RNA 
was measured by real-time quantitative reverse transcription polymerase chain reaction 
(qRT-PCR). We examined mRNA expression in 4 brain regions: cortex, hippocampus, 
amygdala, and PFC. The cortex and PFC have roles in mediating locomotor activity and 
would possibly be affected by repeated diazepam and zolpidem [87]. It is thought that the 
hippocampus and amygdala have roles in mediating withdrawal induced anxiety and 
possibly tolerance from BZs [63, 232, 233].The cortex and prefrontal cortex have been 
found to have changes in mRNA expression due to BZs and zolpidem [107, 109, 111, 
113, 115, 117, 234]. Other studies have found changes in mRNA expression in the 
hippocampus as well [102, 104, 118, 119, 202, 203]. Tolerance and withdrawal from BZs  
 
------------------------------------- 
* Modified with permission. Wright, B.T., C.F. Gluszek, and S.A. Heldt, The effects of repeated 
zolpidem treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile 
expression in mice: comparison with diazepam. Psychopharmacology (Berl), 2014. 231(15): p. 
2967-79 [16]. 
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and zolpidem can also alter total and surface expression of proteins in the cortex and 
hippocampus as measured by western blot [107, 117].  
 
 
Materials 
 
 
Mice 
 
Male C57BL/6J mice about 3-6 months old and weighing about 18-30 g (Jackson 
Laboratories, Maine) were used in these studies. Mice were housed in standard group 
cages (n = 5), allowed full access to food and water, and maintained on a 12 hour 
light/dark cycle (light on from 7:00 a.m.). Once in the vivarium, mice were allowed to 
acclimate there for at least a week before being used in experiments. Experiments were 
performed during the light cycle and were approved by the UTHSC Institutional Review 
Board. All experiments followed the principles and standards of animal care outlined by 
the NIH publication “Guide for the Care and Use of Laboratory Animals” [235].  
 
In Study 1, two cohorts of mice were used for the experiments. Cohort 1 included 
mice treated with vehicle (n = 11), diazepam (n = 11), and zolpidem (n = 12). Cohort 2 of 
Study 1 included mice treated with vehicle (n = 9), diazepam (n = 10), and zolpidem (n = 
9). In Study 2, five cohorts of mice were used for experiments. Cohort 1 included vehicle 
(n = 13), diazepam (n = 13), and zolpidem (n = 13) treated mice. Cohort 2 of Study 2 
included mice treated with vehicle (n = 9), diazepam (n = 9), and zolpidem (n = 8) mice. 
Cohort 3 of Study 2 included mice treated with vehicle (n = 4), diazepam (n = 4), and 
zolpidem (n = 5) mice. Cohort 4 of Study 2 included mice treated with vehicle (n = 6), 
diazepam (n = 8), and zolpidem (n = 9) mice. Cohort 5 of Study 2 included mice treated 
with vehicle (n = 6), diazepam (n = 6), and zolpidem (n = 6) mice. In Study 3, two 
cohorts of mice were used. Cohort 1 was composed of vehicle (n = 6), diazepam (n = 6), 
and zolpidem (n = 7) treated mice and Cohort 2 included mice treated with vehicle (n = 
12), diazepam (n = 10), and zolpidem (n = 19) mice. 
 
 
Drugs and Antibodies 
 
Diazepam, zolpidem (catalog numbers D0899 and Z-103, respectively; Sigma, St 
Louis, MO) and flumazenil (catalog number 1328; Tocris, Bristol, UK) were suspended 
in a vehicle which was composed of saline with 0.05 % Tween-80. Animal weights were 
recorded before all drug injections. Daily injections and behavioral testing were 
conducted in distinct environments to prevent context-specific tolerance [236]. Drugs 
were administered intraperitoneally (i.p.) at a volume of 10 ml/kg. In Studies 1-3 mice 
were treated twice a day (8:00 am and 5:00 pm) with 5 mg/kg of zolpidem, 10 mg/kg of 
diazepam, or vehicle. Treatment doses were based on previous experiments in rats and 
mice designed to study the development of sedative tolerance to diazepam or zolpidem 
[25, 28, 112, 123, 128, 129]. The test dose of zolpidem was selected from dose-response 
curves indicating the 50 % effective dose (ED50) for the locomotor-impairing effects of 
zolpidem in rats and mice ranging from 1.0 to 2.5 mg/kg [72, 224]. The test dose of the 
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GABAAR antagonist flumazenil was used based on prior experiments showing 
flumazenil, at a dose of 10 mg/kg, induces mild withdrawal symptoms like increased 
locomotor activity and anxiety-like behaviors in mice previously given chronic BZ 
treatments [38, 121, 230, 237].  
 
Primary GABAAR subunit antibodies used for cross-linking/western blot analyses 
were as follows: α1 subunit (1:1000; Millipore, Billerica, MA, USA), α2 subunit (1:1000; 
Alomone Labs, Jerusalem, Israel), α3 subunit (1:500; Abcam, Cambridge, UK), and γ2 
subunit (1:1000; Affinity Bioreagents, Waltham, MA). The primary NMDAR subunits 
antibodies used were NR1 subunit (1:1000; Abcam, Cambridge, UK) and NR2A subunit 
(1:400; Millipore, Billerica, MA). Peroxidase labeled anti-rabbit IgG (1:5000) and 
peroxidase labeled anti-mouse IgG (1:5000) were used as secondary antibodies (both 
from Vector Laboratories, Burlingame, CA). An antibody for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, 1:3000; Fitzgerald, Acton, MA) was used as a 
control protein and to normalize results. The GAPDH was a monoclonal mouse antibody 
and the other primary antibodies were polyclonal rabbit antibodies. 
 
 
Justification for Why We Selected 3, 7, and 30 Days as Our Experimental Time 
Points 
 
Most drug studies investigate the behavioral and molecular changes that occur 
after different treatment durations of drugs. Most studies that have looked at zolpidem 
tolerance have examined development after 7-14 days, however there are few that look at 
the effects of short-term or long-term zolpidem treatment. Studies investigating BZ 
tolerance examine tolerance after 1-3 days (short-term), 7-14 days, and > 28 days (long-
term) [122, 127, 130, 131, 151].  
 
 
Justification for Two Injections for Methodology 
 
For this project we decided to give mice two injections to better mimic the high 
dose levels that can occur when humans abuse zolpidem by self-administering multiple 
high doses, sometimes throughout the day [139, 147, 148, 174]. In addition, since mice 
metabolize zolpidem faster than humans, two doses increase the probability of mimicking 
high circulating concentrations that occur in humans abusing zolpidem [31, 33, 37, 39, 
131, 179]. The 50% effective dose (ED50) for zolpidem in rodents needed to impair 
locomotor activity is 1.0-2.5 mg/kg and the ED50 for diazepam is 1.21 mg/kg [72, 224, 
238]. The doses are 10x (zolpidem) or 20x (diazepam) greater than needed to induce 
sedation in mice. Likewise, humans who abuse zolpidem go beyond the clinical dose (5-
10 mg) and can use 10-20 times the clinical dose (100-1000 mg), defined as a 
supratherapeutic dose. 
 
 
  
  
30 
Methods 
 
Figure 3-1 is a simple flow-chart of the experimental designs of Studies 1-3. In 
all studies, mice received treatment injections of vehicle, diazepam, and zolpidem on 
consecutive days (i.e. 3, 7, or 30). All behavioral tests and molecular analyses were 
started 16-20 hours after the last treatment injection, unless otherwise stated. In Study 1, 
two cohorts of mice received vehicle, diazepam, or zolpidem for 3 days. Both cohorts 
were tested for sedative tolerance measured by locomotor activity in the open field. 
Immediately after testing Cohort 2 was given one injection of their assigned drug, then 
sacrificed 16-20 hours later for analysis of mRNA expression. The mRNA expression of 
GABAAR α1-5, β1-3, γ1-2 and δ subunits, GABAA clustering protein gephyrin, and 
GABA transporter 1 (GAT-1) were measured by qRT-PCR.  
 
 In Study 2, five cohorts of mice received vehicle, diazepam, or zolpidem for 7 
days. Cohort 1 was tested for sedative tolerance measured by locomotor activity in the 
open field. Cohort 2 was tested for spontaneous withdrawal measured by locomotor 
activity and anxiety-like behaviors measured in the open field. Cohort 3 was tested for 
flumazenil-induced withdrawal measured by anxiety-like measures in the EPM and open 
field as well as locomotor activity in the open field. Cohort 4 was used for analysis of 
mRNA expression of GABAAR α1-5, β1-3, γ1-2 and δ subunits, gephyrin, GAT-1, 
NMDA subunits (GluN2A, GluN2B, and GluN1), and AMPA subunits (GluR1 and 
GluR2) measured by qRT-PCR. Cohort 5 was used to analyze total protein expression of 
GABAAR subunits α1, α2, α3, and γ2, and the surface expression of GABAAR subunit 
α1. Protein expression was measured by western blot in the cortex and hippocampus. 
  
In Study 3, two cohorts of mice received vehicle, diazepam, or zolpidem for 30 
days. Both cohorts were tested for sedative tolerance measured by locomotor activity in 
the open field. Immediately after testing Cohort 2 was given their assigned drug regimen, 
then sacrificed 16-20 hours later for analysis of mRNA expression of GABAAR α1-5, β1-
3, γ1-2 and δ subunits, gephyrin, and GAT-1 measured by qRT-PCR. A separate cohort 
of mice were for injected for 1 day (acute), to measure the effect of acute diazepam, 
zolpidem, and vehicle on mRNA expression measured by qRT-PCR. 
 
 
Tolerance and Spontaneous Withdrawal: Open Field 
  
Tolerance and spontaneous withdrawal were measured by examining locomotor 
activity during a 60-min open field test session [226]. Mice were given either 2 mg/kg of 
zolpidem (tolerance) or vehicle (spontaneous withdrawal) and placed back in the home 
cage for 2 min prior to testing. A 2-min latency between test drug injection and testing 
onset has been successfully used to identify tolerance to the locomotor-impairing effect 
of the BZ midazolam, which, like zolpidem, is relatively short acting and rapidly 
eliminated [239, 240]. After 2 min, mice were individually placed in open field chambers 
(44.45 cm long, 45.09 cm wide, and 29.21 cm high) constructed from a clear 
polycarbonate and equipped with four 24-beam infrared arrays across the base of each 
chamber wall (MED Associates, Model ENV-520). All measures in the open field were 
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Figure 3-1. Overview flow chart of experimental studies 
The studies were conducted to evaluate the effect of treatment durations on locomotor 
activity, mRNA levels, and protein expression. The mice used in these studies were male 
C57BL/6Js. In Study 1, two cohorts of mice were used, both were used for tolerance and 
cohort 2 was used for qRT-PCR. In Study 2, five cohorts of mice were used, each cohort 
was used in only one experiment. In Study 3, two cohorts of mice were used, both were 
used for tolerance and cohort 2 was used for qRT-PCR 
 
.  
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automatically recorded and collected by the MED Associates’ Activity Monitor Data 
Analysis software installed on an IBM-based computer. For tolerance experiments, the 
horizontal distance (in cm) was recorded and used as an index of motor sedation. For 
withdrawal experiments, horizontal distance, vertical counts (frequency of rearing), time 
spent in the center, and number of center entries were recorded and used as an indices of 
withdrawal. The central zone was defined as the compartment of the floor centrally 
located 8 cm from the perimeter of the chamber walls. Testing was conducted under 
standard test room lighting (100 lux), and each animal was tested once.  
 
 
Flumazenil-Induced Withdrawal: EPM and Open Field 
 
Cohort 3 was used to measure flumazenil-induced withdrawal. After a 7 day 
treatment with diazepam, zolpidem, or vehicle, mice were tested for flumazenil-induced 
withdrawal on two consecutive days. On Day 1, mice were given a 10 mg/kg injection of 
flumazenil 20 min before a 5 min EPM test session. After EPM testing, mice were 
immediately placed in the open field for a 60-min test session. On Day 2 mice were given 
a 10 mg/kg injection of flumazenil 20 min before a 60-min open field test session. Mice 
were then individually placed in open field chambers.  
 
The EPM was constructed of wood, painted white, and consisted of 4 arms that 
were 30.48 cm long and 6.99 cm wide and elevated by a wooden base to a height of 
76.20 cm. Two of the EPM arms were without walls and 2 arms were enclosed by 
17.78cm high walls. Animal movements were recorded overhead with the use of a 
camera (SENTECH). Recordings were analyzed with video-tracking software (ANY-
maze©, Stoelting CO, USA). The anxiety-like behaviors tracked in the EPM were 
percent time spent in the open arms and the number of entries into the open arms. The 
testing in the open field was conducted as stated above in Tolerance and Withdrawal: 
Open Field. For flumazenil-induced withdrawal the dependent variables were the same as 
for spontaneous withdrawal. 
 
 
qRT-PCR 
 
About a day after their last treatment injection, mice were sacrificed by cervical 
dislocation. Immediately afterwards, whole mouse brains were rapidly isolated and 
immediately frozen on crushed dry ice. Tissue isolation was performed by sectioning 
brains (300-μmthick) on a Leica cryostat, followed by dissection of the PFC, cortex, 
amygdala, and the hippocampus using a stereomicroscope and a scalpel blade under 
RNAse-free conditions. After the collection, samples were stored in buffer RLT Lysis 
buffer (QUIAGEN) at −20 °C.  
 
Samples were then homogenized by sonication and RNA was isolated with the 
RNeasy protect mini kit (QIAGEN). RNA concentration and purity were determined 
using a microplate reader in conjunction with a Take3™ Micro-Volume plate (BioTek 
Instruments, Inc., Winooski, VT). The ratio of absorbance at 260 and 280 nm of samples 
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were commonly in the range of 1.8–2.2. Samples with A260/A280 of less than 1.8 were 
considered to be contaminated by protein and excluded from further analyses. RNA 
integrity was determined using the Agilent Bioanalyzer 2100 (Agilent Technologies, UK) 
to generate an electropherogram and an RNA integrity number (RIN). RIN scores ranged 
between 5.3 and 9.4.  
 
RNA was transcribed to cDNA using Transcriptor first-strand cDNA synthesis kit 
(Roche Diagnostics, Indianapolis, IN, USA) following the manufacturer’s instructions. 
One reaction consisted of 2 μL Anchored oligo(dT) primer (2.5 μM), 4 μL random 
hexamer primer (60 μM), 8 μL reaction buffer 5× (8 mM), 1 μL protector TNase inhibitor 
(20 U), 4 μL deoxynucleotide mix (1 mM), and 1 μL reverse transcriptase (10 U). 
Varying volumes of RNA (amounting to 100 ng) and PCR-grade water were added for a 
20-μL reaction mixture. Complementary DNA (cDNA) was transcribed using an 
Eppendorf Mastercycler thermal cycler (Eppendorf) gradient PCR machine. Reverse 
transcription incubation conditions were 25 °C for 10 min, 55 °C for 30 min, and 85 °C 
for 5 min.  
 
The relative expression levels of α1-5, β1-3, γ1-2 and δ subunits, gephyrin, and 
GAT-1 were measured in Studies 1-3. In Study 2 the relative expression levels of 
GluN2A, GluN2B, GluN1, GluR1 and GluR2 were also measured. Measurements for 
mice given acute administration were limited to α1-3, α5, β2, γ2, and GAT-1. Primer and 
probe combinations were designed using ProbeFinder software (version 2.45; Roche 
Diagnostics, Indianapolis, IN, USA). The oligonucleotide sequences used for the primers 
(Integrated DNA Technologies) and gene transcript IDs are shown in Table 3-1[16].  
 
To determine PCR efficiencies, we generated standard curves for each target and 
reference genes (β-tubulin, β-actin, cyclin D, hypoxanthine phosphoribosyltransferase 1, 
ribosomal protein S19, and TATA-binding protein) by plotting the threshold value (Ct) 
versus the log of the amount of serial dilutions of cDNA (2 μg–0.2 ng). Separate standard 
curves were generated for each brain region analyzed. The amplification efficiencies of 
target and reference genes were within an acceptable slope range of −3.6 to −3.1, 
corresponding to efficiencies close to 100%. TATA-binding protein was used as the 
endogenous reference gene and amplified in parallel with target genes. This reference 
gene showed stable expression across samples and between brain regions. PCR 
efficiencies between the target and reference genes were relatively equal. Real-time PCR 
was performed using the TaqMan detection method and LightCycler® 480 System 
(Roche Diagnostics, Indianapolis, IN, USA) [241]. Each reaction was performed in 
triplicate and consisted of 0.1 μL of UPL probe (10 μM), 0.1 μL of forward primer (20 
μM), 0.1 μL of reverse primer (20 μM), 5 μL of LC 480 2X master mix (Roche 
Diagnostics, Indianapolis, IN, USA), 2.7 μL of PCR grade water, and 2 μL of cDNA (10 
ng). The PCR reaction consisted of initial incubations at 95 °C for 5 min followed by 50 
amplification cycles of 95 °C for 10 s, 60 °C for 30 s, and 72 °C for 10s 
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Table 3-1. Gene transcripts and primer sequences 
 
 
The gene transcripts and sequences used in the qRT-PCR experiments. Gabra1-α1 
subunit, Gabra2-α2 subunit, Gabra3-α3 subunit, Gabra4-α4 subunit, Gabra5-α5 subunit, 
Gabrb1-β1 subunit, Gabrb2-β2 subunit, Gabrb3-β3 subunit, Gabrd-δ subunit, Gabrg1-γ1 
subunit, Gabrg2-γ2 subunit, Grin2a-GluN2A, Grin2b-GluN2B, Grin1-GluN1, Gria1-
GluR1, and Gria-GluR2. Modified with permission. Wright, B.T., C.F. Gluszek, and S.A. 
Heldt, The effects of repeated ZOLP treatment on tolerance, withdrawal-like symptoms, 
and GABAA receptor mRNAs profile expression in mice: comparison with DZP. 
Psychopharmacology (Berl), 2014. 231(15): p. 2967-79 [16]. 
 
  
Gene ID Forward Primer Sequence Reverse Primer Sequence Ensembl Transcript ID 
Gabra1 5’-CTT TTC TCC CGG GTC TGG-3’ 5’-TCT TCA TCA CGG GCT TGC-3’ ENSMUST00000169305 
Gabra2 5’-ACA AAA AGA GGA TGG GCT TG-3’ 5’-TCA TGA CGG AGC CTT TCT CT-3’ ENSMUST00000000572 
Gabra3 5’-CTT GGG AAG GCA AGA AGGTA-3’ 5’-GGA GCT GGT GTT TTC TT-3’ ENSMUST00000137517 
Gabra4 5'-AAA GCC TCC CCC AGA AGT T-3' 5'- CAT GTT CAA ATT GGC ATG TGT-3' ENSMUST00000031121 
Gabra5 5’-GAC GGA CTC TTG GAT GGC TA-3’ 5’-ACC TGC GTG ATT CGC TCT-3’ ENSMUST00000068456 
Gabrb1 5'-CCC TCT GGA TGA GCA AAA CT-3' 5'-AAT TCG ATG TCA TCC GTG GTA-3' ENSMUST00000031122 
Gabrb2 5’-CGA TGG CAC TGT CCT GTA TG-3’ 5’-ATA CCG CCT TAG GTC CAT CA-3’ ENSMUST00000169077 
Gabrb3 5'-CGT GGG TGT CCT TCT GGA T-3' 5'-ATG GTG AGC ACG GTG GTA AT-3' ENSMUST00000085240 
Gabrd 5‘-CGGAGCTGATGAACTTCAAAT-3’ 5‘-ATGTAGACGCCCCGGTTC-3' ENSMUSG00000029054 
Gabrg1 5'-AGG CAG GAA GCT GAA AAA CA-3' 5'-TTC ATG GGA ATG AGA GTG GA-3' ENSMUST00000101143 
Gabrg2 5’-ACA GAA AAT GAC GCT GTG GA-3’ 5’-CAT CTG ACT TTT GGC TTG TGA A-3’ ENSMUST00000070725 
GEPHYRIN 5'-TGA TCT TCA TGC TCA GAT CCA-3' 5'-GCA AAT GTT GTT GGC AAG C-3' ENSMUST00000052472 
GAT-1 5’-GCC TGG TCA ATA CCA CCA AC-3’ 5’-CCA TCT GTC ATC TGG TGC AT-3’ ENSMUST00000032454 
Grin2a 5'-ATT CAA CCA GAG GGG CGT A-3' 5'-TTC AAG ACA GCT GCG TCA TAG-3' ENSMUSG00000059003 
Grin2b 5’-GTGAGAGGAAATCTCGGGGC-3’ 5’- GGATGCCGGGGATAGAAAGG-3’ ENSMUSG00000030209 
Grin1 5’-GTCCTCCAAAGACACGAGCA-3’ 5’-AGCTCTCCCTATGACGGGAA-3’ ENSMUSG00000026959 
Gria1 5‘-AGGGATCGACATCCAGAGAG-3' 5‘-TGCACATTTCCTGTCAAACC-3' ENSMUSG00000020524 
Gria2 5‘-CCAATGGGATAAGTTCGCATA-3' 5‘-GCACAGCTTGCAGTGTTGA-3' ENSMUSG00000033981 
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Bissulfosuccinimidyl Suberate (BS3) Cross-Linking/Western Blot 
 
The water soluble protein BS3 reacts with cell-surface proteins to selectively form 
amine bonds on the cell surface. These cross-linked surface proteins can be isolated, 
visualized, and quantified by western blot analysis because they appear at a higher 
molecular weight compared to non-cross-linked intracellular protein [242].  
 
About a day after mice were given their last treatment injection in Study 2, they 
were sacrificed by cervical dislocation. The whole mouse brains were rapidly isolated 
and placed on ice. BS3 cross-linking assays were performed following a protocol 
modified from Boudreau [242]. Tissue isolation was performed by sectioning brains 
(1mm thick) with an acrylic matrix (Brain Tree©), followed by dissection of the left and 
right cortex and hippocampus with a scalpel blade. After dissection, right cortex and 
hippocampus tissue samples were placed in tubes containing artificial cerebrospinal fluid 
(ACSF) and stored on ice. Left cortex and hippocampus samples were placed in tubes 
containing a 52mM BS3/ACSF solution and incubated for 30 min in a 4⁰C refrigerator 
with gentle mixing. After BS3 incubation, the tissue was quenched in 100mM glycine 
solution and placed back into the 4⁰C refrigerator for a 10 min gentle mixing period. 
After quenching was completed, BS3 treated and non-treated tissue samples were spun 
down in for 2 min and the supernatant was discarded. Cortical and hippocampal BS3 
treated and untreated tissue samples were placed in lysis buffer containing protease and 
phosphatase inhibitors (Complete ULTRA tablets, Roche Diagnostics, Indianapolis, IN, 
USA) and sonicated to lyse cells. Samples were again spun down and supernatant was 
collected. The protein concentration was quantified by the PierceTM BCA protein assay 
kit (ThermoFisher Scientific, Waltham, MA). 
 
Equal amounts of protein (20 mg) were separated by SDS-PAGE and then 
transferred to a nitrocellulose membrane (Bio-Rad). After transfer, the membrane was 
blocked with tris-buffered saline with 0.05% Tween 20 (TBST) containing 5% milk for 1 
hr at room temperature. After the membrane was blocked, it was incubated with primary 
antibody (α1, α2, α3, γ2, GluN1, GluN2B) diluted in TBST, overnight at 4⁰C. The 
membrane was washed three times in TBST, and incubated with horseradish peroxidase-
conjugated second antibody diluted in TBST at room temperature for 1 hr. After 
incubation, the membrane was washed three times in TBST. Proteins were visualized by 
an enhanced chemiluminescence detection system (Pierce ECL Western Blotting 
Substrate, Thermo Fisher Scientific GermanyLtd. & Co.KG) and images were taken with 
a gel imaging system (Alpha Innotech,Thermo Fisher Scientific GermanyLtd. & Co.KG). 
The GAPDH antibody (Fitzgerald) diluted in TBST was used as a control protein. The 
results of western blotting were analyzed by the AlphaView software system. All results 
were normalized with GAPDH. 
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Data Reduction and Statistical Analyses 
 
 
Tolerance, Spontaneous, and Flumazenil-Induced Withdrawal. In Studies 1-3, 
group differences in tolerance were assessed by analyses on distance traveled during each 
10-min block using a two-way ANOVA with treatment (VEH, DZP, and ZOLP) as the 
between-subject factors and time (Blocks 1–6) as a within-subject factor. Follow-up 
analyses were done with one-way ANOVAs and Dunnett’s t-tests where appropriate.  
 
For spontaneous withdrawal, two-way ANOVAs were conducted on distance 
traveled in the center, periphery, and entire apparatus. These ANOVA were performed to 
assess whether distance traveled across the test session time (Blocks 1–6) influenced 
measures of open-field anxiety. Two-way ANOVAs were conducted on each of the 
following anxiogenic measures; frequency of rearing, number of center zone entries, and 
percent of center zone time during each 10-min block. The between-subject factor was 
treatment (VEH, DZP, and ZOLP) and the within-subject factor was time (Blocks 1–6). 
Follow-up analyses were done with one-way ANOVAs and Dunnett’s t-tests where 
appropriate on each measure. 
 
For flumazenil-induced withdrawal, analyses were conducted on percent time 
open arm time and entries into open arms EPM using a one-way ANOVA for each 
measure. Distance traveled, frequency of rearing, number of center zone entries, and 
percent of center zone time during each 10-min block on each day were analyzed using 
two-way ANOVAs for with treatment (VEH, DZP, and ZOLP) as between-subject 
factors and time (blocks 1–6) as a within-subject factor for each measure. Follow-up 
analyses were done with one-way ANOVAs and Dunnett’s t-tests where appropriate for 
each open field measure. 
 
 
mRNA and Protein Expression. Calculations of standard curves, CT values, and 
quantification of mRNA expression levels were performed by Gene Scanning software 
(version 1.5.0) provided with the LightCycler® 480 Instrument (Roche Applied Science). 
The comparative CT method (ΔΔCT = ΔCT reference-ΔCT target) was used to compare 
expression levels of mRNAs between the control (VEH) and treatment (ZOLP and DZP) 
groups. For ease of presentation, data in tables and figures are expressed as relative fold 
change by applying the 2-ΔΔCT equation. Statistical comparisons were carried out for 
each analyzed region (cortex hippocampus, amygdala, and prefrontal cortex) and 
treatment protocol independently. Statistical analyses for mRNA and protein expression 
in the cortex and hippocampus were performed using one-way ANOVAs with Dunnett's 
t-tests for pairwise comparisons against a single control (VEH) to maintain a 0.05 error 
rate for each analysis. In vehicle-treated animals, the relative abundance of mRNA was as 
follows: cortex, α1 > γ2 > β2 > α3 > α4 > β3 > δ > α5 > β1 > α2 > γ1; hippocampus, γ2 > 
α5 > β3 > α1 > β2 > α4 > β1 > α2 > α3 > δ > γ1; amygdala, γ2 > α3 > β2 > α1 > β3 > α4 
> γ1 > β1 > α5 > α2 > δ; and PFC, α1 > α3 > γ2 > β2 > β3 > α2 > β1 > α5 > δ > α4 > γ1.   
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CHAPTER 4.    RESULTS* 
 
 
Study 1: The Effect of 3-Day Zolpidem and Diazepam Treatment on Behavioral 
Sedation and mRNA Expression 
 
 
Tolerance to the Sedative Effects of Zolpidem 
  
The purpose of Study 1 was to examine if a 3-day treatment regimen of zolpidem 
or diazepam induces significant changes to the sedative effects of zolpidem, as measured 
by open field activity, and significant changes in mRNA expression, as measured by 
qRT-PCR. Alterations to the sedative effects were examined in Cohort 1 and 2 mice 
previously treated with vehicle, diazepam, or zolpidem (Figure 4-1). A two-way 
ANOVA found significant effects of time (Blocks), F(5, 290) = 44.94, p < 0.01, 
treatment (VEH, DZP, ZOLP), F(2, 58) = 4.08, p < 0.05, and a significant interaction of 
Time x Treatment, F(10, 290) = 3.79, p < 0.01. The main effect of time indicated that 
activity between Blocks differ from each other, generally increasing over time. The main 
effect of treatment indicated significant differences between treatment groups in overall 
activity, independent of time. One-way ANOVAs performed at each level of time 
revealed significant differences at Blocks 2 and 3, F(2, 58) = 10.84, p < 0.01 and F(2, 58) 
= 6.20, p < 0.01, respectively. There were no differences at Blocks 1 and 4-6, Fs(2, 58) < 
6.20, ps > 0.05. Follow-up Dunnett’s t-tests with VEH mice as controls showed the DZP 
mice displayed more activity at Blocks 2 and 3 than the VEH mice, ps < 0.05. These 
analyses indicated that after 3 days of diazepam, but not zolpidem, tolerance to 
zolpidem’s sedative effects occur. 
 
 
Changes in mRNA Expression Measured by qRT-PCR 
 
Cohort 2 mice were used to examine changes in mRNA expression. One-way 
ANOVAs were used to compare group levels of each mRNA in the cortex, hippocampus, 
amygdala, and PFC. These ANOVAs revealed no significant differences in levels of any 
GABAAR subunit mRNA or GABAAR-related mRNA in the cortex, Fs(2, 24) < 1.3, ps > 
0.05, amygdala, Fs(2, 19) < 0.94, ps > 0.05, or PFC, Fs(2, 25) < 1.9, ps > 0.05 (Figure  
4-2).  
 
In the hippocampus, there was a significant treatment effect on the expression of 
α5-GABAAR mRNA, F(2, 24) = 3.45, p < 0.05. A Dunnett’s t-test showed the ZOLP 
group had reduced α5-subunit expression compared to the VEH group, p < 0.05. There 
were no significant treatment differences in the levels of other mRNA, Fs(2, 24) < 3.45, 
ps > 0.05 (Figure 4-3). 
------------------------------------ 
*Modified with permission. Wright, B.T., C.F. Gluszek, and S.A. Heldt, The effects of repeated 
zolpidem treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile 
expression in mice: comparison with diazepam. Psychopharmacology (Berl), 2014. 231(15): p. 
2967-79 [16].  
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Figure 4-1. Decreased locomotor impairing effect of zolpidem after 3-day 
administration of zolpidem, diazepam, or vehicle 
Distance traveled in open field after test administration of 2 mg/kg of ZOLP in mice 
previously given subchronic treatment of ZOLP, DZP, or VEH. Analyses of each 10-min 
block showed that differences between groups were most evident in the first half of the 
60-min test session. Data are presented as mean + sem. Number sign denotes VEH < 
DZP groups (p < 0.05). 
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Figure 4-2. Relative levels of mRNA in the cortex, amygdala, and pfc following 3-
day administration of zolpidem, diazepam, or vehicle 
Histograms comparing levels of transcripts are expressed as mean percentage of VEH 
control (100%). Statistical analyses were performed by ANOVA with Dunnett’s t-test for 
pairwise comparisons against a VEH for (A) cortex, (B) amygdala, and (C) pfc. Data are 
presented as mean + sem. There was no significance among these regions, p > 0.05. 
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Figure 4-3. Relative levels of mRNA in the hippocampus following 3-day 
administration of zolpidem, diazepam, or vehicle 
Histograms comparing levels of transcripts are expressed as mean percentage of VEH 
control (100 %). Statistical analyses were performed by ANOVA with Dunnett’s t-test for 
pairwise comparisons against a VEH. Data are presented as mean + sem. Ampersand 
denotes VEH > ZOLP treatments (p < 0.05.). 
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In summary, results from Study 1 indicated that the sedative effects of zolpidem 
was significantly reduced in mice given diazepam for 3 days. The decreased sedative 
efficacy of zolpidem in mice given prior exposure to diazepam is indicative of cross-
tolerance. In contrast, the efficacy of zolpidem was unaffected in mice previously given 
zolpidem, suggesting no tolerance developed in these mice. There were no significant 
changes in the expression of GABAAR subunit or associated mRNAs in the cortex, 
hippocampus, amygdala, or PFC after 3 days of diazepam. However, the expression of 
α5-GABAAR mRNA was reduced in the hippocampus after 3 days of zolpidem 
treatment. 
 
 
Study 2: The Effect of 7-Day Zolpidem and Diazepam Treatment on Behavioral 
Sedation, Withdrawal, mRNA, and Protein Expression 
 
The purpose of Study 2 was to examine if a 7-day treatment regimen of zolpidem 
or diazepam causes 1) changes in the sedative effect of zolpidem, 2) spontaneous 
withdrawal after discontinuation of treatment, 3) flumazenil-induced withdrawal, 4) 
changes in mRNA expression measured by qRT-PCR, and/or 5) changes in total and cell 
surface expression of selective receptor subunits, as measured by western blotting.  
 
 
Tolerance to the Sedative Effects of Zolpidem 
 
Changes to the sedative effects of zolpidem were examined in Cohort 1 mice that 
were previously treated with vehicle, diazepam, or zolpidem. A two-way ANOVA 
yielded significant main effects of treatment, F(2, 46) = 3.40, p < 0.05, time, F(5, 230) = 
118.80, p < 0.01, and a reliable Treatment × Time interaction, F(10, 230) = 8.00, p < 
0.01, signifying performance over time was differentially affected by drug treatment. To 
assess the interaction, one-way ANOVAs at each level of time were performed. These 
tests revealed group differences at Blocks 1, 2 and 3, F(2,46) = 8.16, p < 0.01; F(2,46) = 
16.34, p < 0.01; and F(2,46) = 6.61 p < 0.01, respectively. Follow-up Dunnett’s t-tests 
revealed that the activity in ZOLP and DZP groups was significantly greater than in the 
VEH group at Blocks 1–3, ps < 0.05 (Figure 4-4). There were no group differences at 
Blocks 4-6, Fs(2,36) < 3.05, ps > 0.05.  
 
 
Spontaneous Withdrawal  
 
The presence of spontaneous withdrawal after discontinued zolpidem, diazepam, 
or vehicle treatments was assessed in Cohort 2. We looked at overall activity to 
determine if mice had the differences in the rate of habituation over time, which might 
confound our interpretation of results. A 2-way ANOVA found no significant main effect 
of time, F(5,105) = 0.01, p > 0.05, no main effect of treatment, F(2,21) = 0.02, p > 0.05, 
and no significant interaction of Time x Duration, F(10,105) = 0.11, p > 0.01. The 
analysis for rate of habituation show that all groups show a similar rate of habituation.  
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Figure 4-4. Decreased locomotor impairing effect of zolpidem after 7-day 
administration of zolpidem, diazepam, or vehicle 
Distance traveled in open field after test administration of 2 mg/kg of ZOLP in mice 
previously given subchronic treatment of ZOLP, DZP, or VEH. Analyses of each 10-min 
block showed that differences between groups were most evident in the first half of the 
60-min test session. Data are presented as mean + sem. Black star denotes VEH-ZOLP < 
ZOLP-ZOLP and DZP-ZOLP groups (p < 0.05). Reprinted with permission. Wright, 
B.T., C.F. Gluszek, and S.A. Heldt, The effects of repeated ZOLP treatment on tolerance, 
withdrawal-like symptoms, and GABAA receptor mRNAs profile expression in mice: 
comparison with DZP. Psychopharmacology (Berl), 2014. 231(15): p. 2967-79 [16]. 
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For distance traveled in the entire open field, a two-way ANOVA found that there 
was a main effect of time, F(5,105) = 34.78, p < 0.01, a main effect of treatment, F(2,21) 
= 8.08, p < 0.01, and a significant interaction of Time x Duration, F(10,105) = 2.97, p < 
0.01. To assess the interaction, a one-way ANOVAs at each level of time were 
performed. There were group differences at Block 1, F(2,21) = 16.82, p < 0.01, Block 2, 
F(2,21) = 8.25, p < 0.01, Block 3,  F(2,21) = 4.29, p < 0.05, and Block 5, F(2,21) = 4.70, 
p < 0.05. Follow-up Dunnett’s t-tests revealed that the activity of ZOLP and DZP groups 
was significantly lower than the VEH groups at Blocks 1 and 2, p < 0.01 and the activity 
of DZP groups was significantly lower than the VEH groups at Blocks 3 and 5, p < 0.05. 
There was no significantly differences at Blocks 4 and 6, Fs (2,21) > 3.11, p > 0.05 
(Figure 4-5). 
 
For percent of center zone time, a two-way ANOVA yielded main effects of 
treatment, F(2, 23) = 5.27; p < 0.02, time, F(5, 115) = 8.36; p < 0.01, and a significant 
Treatment × Time interaction, F(10, 115) = 2.49; p = 0.01. One-way ANOVAs followed 
by Dunnett’s t-tests indicated significant differences during Blocks 4-6, F(2,23) = 7.82, p 
< 0.01; F(2,23) = 4.25, p < 0.05; and F(2,23) = 5.95, p < 0.01. There were no significant 
differences between groups at Blocks 1-3, F(2,23) < 3.3, p > 0.05. Overall, ZOLP and 
DZP groups spent significantly less percent of time in the center zone in Blocks 4-6 
compared to VEH mice, ps < 0.01 (Figure 4-6).  
 
For the number of center zone entries, a two-way ANOVA yielded, main effects 
of treatment, F(2, 23) = 8.20; p < 0.01, and time, F(5, 115) = 41.67; p < 0.01, were 
significant. The Treatment × Time interaction, F(10, 115) = 2.67; p < 0.01 was also 
significant. ANOVAs followed by t-tests indicated that ZOLP and DZP groups had fewer 
center zone entries during Blocks 1 and 2 (Figure 4-6). Analyses of frequency of rearing 
showed reliable effects of time, F(5, 115) = 6.28; p < 0.01, and treatment, F(2, 23) = 
41.67; p < 0.01. Overall, the frequency of rearing was lower in both ZOLP and DZP 
groups in comparison to the VEH group (Figure 4-6).  
 
 
Flumazenil-Precipitated Withdrawal  
 
Cohort 3 mice were used to assess the presence of flumazenil-precipitated 
withdrawal symptoms on two consecutive days (Day1 and Day 2) after vehicle, 
diazepam, or zolpidem treatments. On Day 1, mice were given flumazenil (10 mg/kg/i.p) 
20 min before EPM and subsequent open field testing. One-way ANOVA analyses of 
EPM measures revealed no significant differences between groups for percent time in the 
open arms or entries into the open arms, Fs(2,10) < 1.38, ps > 0.05 (Figure 4-7) Group 
differences in Day 1 open field dependent measures were assessed using two-way 
ANOVAs. For distance traveled, this analysis indicated a significant effect of time, 
F(5,45) = 52.21, p < 0.01, and a significant interaction of Time x Treatment, F(10,45) = 
2.18, p < 0.05. There was no significant effect of treatment, F(2,9) = 1.13, p > 0.05. A 
one-way ANOVA found significant group differences at Block 6, with ZOLP and DZP 
groups displaying less activity than the VEH group, ps < 0.05 (Figure 4-8). For percent 
time spent in the open field center zone, analysis indicated a significant effect of time,  
  
44 
 
 
Figure 4-5. Decreased locomotor activity in zolpidem and diazepam groups after 
cessation of 7 days of zolpidem and diazepam 
Distance traveled in open field after test administration of VEH in mice previously given 
subchronic treatment of ZOLP, DZP, or VEH. Analyses of each 10-min block showed 
that differences between groups were most evident in the first half of the 60- min test 
session. Data are presented as mean + sem. Black star denotes VEH> ZOLP and DZP 
groups (p < 0.05). Number sign denotes VEH > DZP group (p < 0.05). Reprinted with 
permission. Wright, B.T., C.F. Gluszek, and S.A. Heldt, The effects of repeated ZOLP 
treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile 
expression in mice: comparison with DZP. Psychopharmacology (Berl), 2014. 231(15): 
p. 2967-79 [16].  
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Figure 4-6. Decreased percent time in center, center entries, and rearing 
frequency after cessation of 7 days of zolpidem and diazepam 
Multiple exploratory behaviors were decreased following cessation of drug. (A) Percent 
of center time, (B) Number of center entries, and (C) Rearing frequency. Analyses were 
conducted on means of each 10-min block. Data are presented as mean + sem. Black star 
denotes VEH significantly different than ZOLP and DZP groups (p < 0.05). Reprinted 
with permission. Wright, B.T., C.F. Gluszek, and S.A. Heldt, The effects of repeated 
ZOLP treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs 
profile expression in mice: comparison with DZP. Psychopharmacology (Berl), 2014. 
231(15): p. 2967-79 [16].  
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Figure 4-7. Percent time spent and percent entries into the open arms of the EPM 
after acute flumazenil administration after 7-day administration of zolpidem, 
diazepam, or vehicle 
Histogram comparing (A) percent of time spent in the open arms and (B) percent entries 
into the EPM. Statistical analyses were performed by ANOVA with Dunnett’s t-test for 
pairwise comparisons against a VEH. Data are presented as mean + sem. There were no 
significant differences between the groups (p > 0.05).  
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Figure 4-8. Locomotor effect of flumazenil on test day 1 after 7-days 
administration of zolpidem, diazepam, or vehicle 
Distance traveled in open field after test administration of FLU in mice previously given 
subchronic treatment of ZOLP, DZP, or VEH on test day 1. Analyses were conducted on 
means of each 10- min block. There was a significant decrease in activity at Block 6 on 
day 1, but no significant differences between groups on day 2. Data are presented as 
mean + sem. Black star denotes VEH significantly different than ZOLP and DZP groups 
(p < 0.05).  
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F(5,45) = 45.41, p < 0.01, but no significant effect of treatment, F(2,9) = 0.83, p > 0.05, 
or a significant interaction of Time x Treatment, F(10,45) = 1.31, p > 0.05 (Figure 4-9). 
For center entries, the analysis indicated a significant effect of time, F(5,45) = 22.70, p < 
0.01, but no significant effect of treatment, F(2,9) = 2.83, p > 0.05, or a significant 
interaction of Time x Treatment, F(10,45) = 0.38, p > 0.05 (Figure 4-9). For frequency 
of rearing on Day 1, analysis indicated a significant effect of time, F(5,45) = 23.01, p < 
0.01, but no significant effect of treatment, F(2,9) = 1.54, p > 0.05, or a significant 
interaction of Time x Treatment, F(10,45) = 0.40, p > 0.05 (Figure 4-9). 
0.05). Data are presented as mean + sem.  
 
On Day 2, mice were given of flumazenil (10 mg/kg/i.p) 20 min before open field 
testing, and group differences in dependent measures were assessed using two-way 
ANOVAs. The analysis of group difference in distance traveled showed a significant 
effect of time, F(5,50) =18.76, p < 0.01, but no significant effect of treatment, F(2, 10) = 
0.627, p > 0.05 or a significant interaction of Time x Treatment, F(10,50) = 0.933, p > 
0.05 (Figure 4-10). For percent time spent in center on Day 2, analysis indicated a 
significant effect of time, F(5,50) = 4.41, p < 0.01 but no significant effect of treatment, 
F(2,10) = 0.791, p > 0.05 or significant interaction of Time x Treatment, F(10,50) = 0.21, 
p > 0.05 (Figure 4-11). For center entries, analysis indicated a significant effect of time, 
F(5,50) = 20.03, p < 0.01, and a significant interaction of Time x Treatment, F(10,50) = 
3.33, p > 0.01, but no significant effect of treatment, F(2,10) = 0.61, p > 0.05. A one-way 
ANOVA found significant group differences at Block 1, F(2,10) = 4.38, p < 0.05, with 
the ZOLP group having less center entries than the VEH groups (Figure 4-11). There 
were no significant group differences at Blocks 2-6, F(2,10) <4.32, p > 0.05. For 
frequency of rearing, t analysis indicated a significant effect of time, F(5,50) = 5.46, p < 
0.01 but no significant effect of treatment F(2,10) = 0.45, p > 0.05 or a significant 
interaction of Time x Treatment, F(10,50) = 2.01, p > 0.05 (Figure 4-11). 
 
 
Changes in mRNA Expression Measured by qRT-PCR 
 
Cohort 4 was used to measure changes in mRNA expression of GABAAR 
subunits and related proteins in the cortex, hippocampus, amygdala, and PFC. In the 
cortex (Figure 4-12), a one-way ANOVA identified group differences for the subunits 
α1, F(2, 17) = 12.97, p < 0.01; α3, F(2, 17) = 6.92, p < 0.01; β2, F(2, 17) = 5.80, p < 
0.05, and δ, F(2, 17) = 5.93, p < 0.05. Follow-up Dunnett’s t tests revealed decreased 
expression levels of α1, α3, β2, and δ subunits in ZOLP and DZP groups compared to 
VEH (ps < 0.05) and DZP groups but not ZOLP groups, induced significant decreases in 
expression of α4, α5, β1, and γ2 subunits after chronic treatment (ps < 0.05). In addition 
to subunits, group differences were identified for gephyrin, F(2, 17) = 4.95, p < 0.05, and 
GAT-1, F(2, 17) = 5.80, p < 0.05.There were no significant differences for the other 
subunits, Fs(2, 17) < 4.39, ps > 0.05.  
 
In the hippocampus (Figure 4-13), a one-way ANOVA identified group 
differences for the α5 subunit, F(2, 18) = 3.82, p < 0.05 and γ2 subunit, F(2, 17) = 5.22, p 
< 0.05. Follow-up Dunnett’s t tests revealed decreased expression levels of α5 and γ2  
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Figure 4-9. Effect of flumazenil on percent time in center, center entries, and 
rearing frequency on test day 1 after 7-days administration of zolpidem, diazepam, 
or vehicle 
Percent time in center, center entries, and rearing frequency in open field after test 
administration of FLU in mice previously given subchronic treatment of ZOLP, DZP, or 
VEH on test day 1. Analyses were conducted on means of each 10- min block. There 
were no significant differences between the groups on day 1 (p > 0.05). Data are 
presented as mean + sem.  
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Figure 4-10. Locomotor effect of flumazenil test day 2 after 7-day administration 
of zolpidem, diazepam, or vehicle 
Distance traveled in open field after test administration of FLU in mice previously given 
subchronic treatment of ZOLP, DZP, or VEH day 2. Analyses were conducted on means 
of each 10- min block. There were no significant differences between groups, p > 0.05. 
Data are presented as mean + sem.  
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Figure 4-11. Effect of flumazenil on percent time in center, center entries, and 
rearing frequency on test day 2 after 7-days administration of zolpidem, diazepam, 
or vehicle 
Percent time in center, center entries, and rearing frequency in open field after test 
administration of FLU in mice previously given subchronic treatment of ZOLP, DZP, or 
VEH on test day 2. Analyses were conducted on means of each 10- min block. There 
were significant group differences on the number of center entries at Block 1. ZOLP 
groups had less center entries than VEH groups. There were no significant group 
differences at other measures, p > 0.05. Data are presented as mean + sem. Ampersnad 
denotes VEH significantly different than ZOLP and DZP groups (p < 0.05).  
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Figure 4-12. Relative levels of mRNA in the cortex following 7-day administration 
of zolpidem, diazepam, or vehicle 
Histograms comparing levels of transcripts are expressed as mean percentage of VEH 
control (100%). Statistical analyses were performed by ANOVA with Dunnett’s t test for 
pairwise comparisons against a VEH. Data are presented as mean + sem. Black star 
denotes VEH significantly different than ZOLP and DZP treatments (p < 0.05); Number 
sign denotes VEH significantly different than DZP treatment (p < 0.05). Reprinted with 
permission. Wright, B.T., C.F. Gluszek, and S.A. Heldt, The effects of repeated ZOLP 
treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile 
expression in mice: comparison with DZP. Psychopharmacology (Berl), 2014. 231(15): p. 
2967-79 [16].   
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Figure 4-13. Relative levels of mRNA in the hippocampus following 7-day 
administration of zolpidem, diazepam, or vehicle 
Histograms comparing levels of transcripts are expressed as mean percentage of VEH 
control (100 %). Statistical analyses were performed by ANOVA with Dunnett’s t test for 
pairwise comparisons against a VEH. Data are presented as mean + sem. Black star 
denotes VEH significantly different than ZOLP and DZP treatments (p < 0.05); Number 
sign denotes VEH significantly different than DZP treatment (p < 0.05). Reprinted with 
permission. Wright, B.T., C.F. Gluszek, and S.A. Heldt, The effects of repeated ZOLP 
treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile 
expression in mice: comparison with DZP. Psychopharmacology (Berl), 2014. 231(15): p. 
2967-79 [16].  
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subunits in DZP groups compared to VEH groups (ps < 0.05). There were no significant 
differences for the other subunits, Fs(2, 18) < 5.22, ps > 0.05. There were no significant 
group differences in the amygdala, Fs(2, 20) < 1.90, ps > 0.05, or the PFC, Fs(2, 20) < 
0.95, ps > 0.05 for the other subunits (Figure 4-14). 
 
 The mRNA expression of AMPAR and NMDAR subunits in the cortex, 
hippocampus, amygdala, and PFC was also measured in Cohort 4. In the hippocampus, a 
one-way ANOVA showed significant differences between groups for GluN2A, F(2,16) = 
4.650, p < 0.05. Follow-up Dunnett’s t-test found that there was a decrease in GluN2A in 
the DZP group compared to the VEH group, p < 0.05 (Figure 4-15). There were no 
significant group differences for other AMPA or NMDA subunits in the hippocampus. 
Likewise, there were no group differences in the cortex, Fs(2, 12) < 0.625, ps > 0.05; 
amygdala, Fs(2, 16) < 0.76, ps > 0.05; or the PFC, Fs(2, 20) < 1.73, ps > 0.05 for the 
other subunits (Figure 4-16). 
 
 
Changes in Total and Surface Subunit Protein Expression 
 
Cohort 5 mice who were given previous zolpidem, diazepam, and vehicle 
treatment were used to measure differences in cortical and hippocampal protein 
expression. In the cortex, one-way ANOVAs found significant differences between 
groups for total α2 subunit, F(2,15) = 4.95, p < 0.05, and γ2, F(2, 6) = 18.16, p < 0.01. In 
the cortex, Dunnett’s t-tests found that total α2 subunit expression is decreased in ZOLP 
mice and total γ2 subunit expression is decreased in DZP mice (Figures 4-17 and 4-18). 
ANOVAs revealed no groups differences in total α1, F (2,15) = 2.47, p > 0.05; total α3, F 
(2,6) = 1.30, p > 0.05; total GluN1, F(2,5) = 0.235, p > 0.05; and total GluN2B, F(2, 5) = 
2.50, p > 0.05(Figures 4-19 through 4-22). A one-way ANOVA found significant 
differences between groups for intracellular α1, F(2,6) = 5.49, p < 0.05 and intracellular 
α1 was decreased in DZP groups, p < 0.05. A one-way ANOVA found no group 
differences with surface α1 subunits F(2,6) =0.176, p > 0.05, (Figure 4-23). In the 
hippocampus one-way ANOVAs found no significant differences between groups for 
total α1, F (2,5) = 2.72, p > 0.05 or total α2, F (2,5) = 3.37, p > 0.05(Figures 4-24 and  
4-25). 
 
In addition to the parametric tests, non-parametric tests were run for the data sets 
for total α1 in the cortex and total α2 in the hippocampus did not meet the assumptions 
needed for conducting parametric tests, therefore non-parametric tests were used for 
analysis. Non-parametric tests using Kruskal-Wallis H test showed that there were no 
significant differences in protein expression between the treatment groups for total α1, 
χ2(2) = 4.82, p > 0.05, and for total α2, χ2(2) = 5.14, p > 0.05. 
 
In summary, mice previously given zolpidem or diazepam treatment for 7 days 
were less sensitive to the sedative effects of zolpidem treatment when compared to 
vehicle mice, indicating the presence of tolerance and cross-tolerance, respectively. 
Zolpidem and diazepam treated mice given vehicle injections prior to testing showed 
evidence of spontaneous withdrawal. Specifically, these mice displayed anxiety-like  
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Figure 4-14. Relative levels of mRNA in the amygdala and pfc following 7-day 
administration of zolpidem, diazepam, or vehicle 
Histograms comparing levels of transcripts are expressed as mean percentage of VEH 
control (100 %). Statistical analyses were performed by ANOVA with Dunnett’s t test for 
pairwise comparisons against a VEH in the (A) amygdala and (B) pfc. Data are presented 
as mean + sem. There were no significant differences between groups, ps > 0.05. 
Reprinted with permission. Wright, B.T., C.F. Gluszek, and S.A. Heldt, The effects of 
repeated ZOLP treatment on tolerance, withdrawal-like symptoms, and GABAA receptor 
mRNAs profile expression in mice: comparison with DZP. Psychopharmacology (Berl), 
2014. 231(15): p. 2967-79 [16].  
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Figure 4-15. Relative levels of mRNA in the hippocampus following 7-day 
administration of zolpidem, diazepam, or vehicle 
Histograms comparing levels of transcripts are expressed as mean percentage of VEH 
control (100 %). Statistical analyses were performed by ANOVA with Dunnett’s t test for 
pairwise comparisons against a VEH. Data are presented as mean + sem. Number sign 
denotes VEH significantly different than DZP treatment (p < 0.05).  
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Figure 4-16. Relative levels of mRNA in the cortex, amygdala, and pfc following 7-
day administration of zolpidem, diazepam, or vehicle 
Relative expression of protein from each group.Histograms comparing levels of 
transcripts are expressed as mean percentage of VEH control (100 %). Statistical analyses 
were performed by ANOVA with Dunnett’s t test for pairwise comparisons against a 
VEH in the (A) cortex, (B) amygdala, and (C) pfc. Data are presented as mean + sem. 
There were no significant differences between groups, ps > 0.05.  
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Figure 4-17. Relative α2 subunit expression in the cortex following 7-day 
administration of zolpidem, diazepam, or vehicle 
Relative expression of protein from each group. Histograms comparing levels of 
transcripts are expressed as mean percentage of VEH control (100%). Statistical analyses 
were performed by ANOVA with Dunnett’s t test for pairwise comparisons against a 
VEH. Data are presented as mean + sem. There were significant differences between 
groups, ps < 0.05. The ZOLP group had less α2 protein expression the VEH group, p < 
0.05.  
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Figure 4-18. Relative γ2 subunit expression in the cortex following 7-day 
administration of zolpidem, diazepam, or vehicle 
Relative expression of protein from each group. Histograms comparing levels of 
transcripts are expressed as mean percentage of VEH control (100%). Statistical analyses 
were performed by ANOVA with Dunnett’s t test for pairwise comparisons against a 
VEH. Data are presented as mean + sem. There were significant differences between 
groups, ps < 0.05. The DZP group had less γ2 protein expression the VEH group, p < 
0.05.  
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Figure 4-19. Relative α1 subunit expression in the cortex following 7-day 
administration of zolpidem, diazepam, or vehicle 
Relative expression of protein from each group. Histograms comparing levels of 
transcripts are expressed as mean percentage of VEH control (100%). Statistical analyses 
were performed by ANOVA with Dunnett’s t test for pairwise comparisons against a 
VEH. Data are presented as mean + sem. There were no significant differences between 
groups, ps > 0.05.  
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Figure 4-20. Relative α3 subunit expression in the cortex following 7-day 
administration of zolpidem, diazepam, or vehicle 
Relative expression of protein from each group. Histograms comparing levels of 
transcripts are expressed as mean percentage of VEH control (100%). Statistical analyses 
were performed by ANOVA with Dunnett’s t test for pairwise comparisons against a 
VEH. Data are presented as mean + sem. There were no significant differences between 
groups, ps > 0.05.  
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Figure 4-21.  Relative GluN1 subunit expression in the cortex following 7-day 
administration of zolpidem, diazepam, or vehicle 
Relative expression of protein from each group. Histograms comparing levels of 
transcripts are expressed as mean percentage of VEH control (100%). Statistical analyses 
were performed by ANOVA with Dunnett’s t test for pairwise comparisons against a 
VEH. Data are presented as mean + sem. There were no significant differences between 
groups, ps > 0.05.  
  
63 
 
 
Figure 4-22. Relative GluN2A subunit expression in the cortex following 7-day 
administration of zolpidem, diazepam, or vehicle 
Relative expression of protein from each group. Histograms comparing levels of 
transcripts are expressed as mean percentage of VEH control (100%). Statistical analyses 
were performed by ANOVA with Dunnett’s t test for pairwise comparisons against a 
VEH. Data are presented as mean + sem. There were no significant differences between 
groups, ps > 0.05.  
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Figure 4-23. BS3 treated samples, surface and intracellular α1 protein expression 
levels in the cortex following 7-day administration of zolpidem, diazepam, or vehicle 
Relative expression of protein from each group. Histograms comparing levels of 
transcripts are expressed as mean percentage of VEH control (100%). Statistical analyses 
were performed by ANOVA with Dunnett’s t test for pairwise comparisons against a 
VEH. Data are presented as mean + sem. There were no significant differences between 
groups, ps > 0.05.  
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Figure 4-24. Relative α1 protein expression levels in the hippocampus following 7-
day administration of zolpidem, diazepam, or vehicle 
Relative expression of protein from each group. Histograms comparing levels of 
transcripts are expressed as mean percentage of VEH control (100%). Statistical analyses 
were performed by ANOVA with Dunnett’s t test for pairwise comparisons against a 
VEH. Data are presented as mean + sem. There were no significant differences between 
groups, ps > 0.05.  
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Figure 4-25. Relative α2 protein expression levels in the hippocampus following 7-
day administration of zolpidem, diazepam, or vehicle 
Relative expression of protein from each group. Histograms comparing levels of 
transcripts are expressed as mean percentage of VEH control (100%). Statistical analyses 
were performed by ANOVA with Dunnett’s t test for pairwise comparisons against a 
VEH. Data are presented as mean + sem. There were no significant differences between 
groups, ps > 0.05.  
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behaviors, including decreases in activity, frequency of rearing, and center zone entries. 
These mice also showed a progressive decrease percent of time in center zone, suggesting 
a gradual increase in anxiety during testing. In contrast, zolpidem and diazepam treated 
mice showed minimal withdrawal symptoms after flumazenil treatment, as indicated by 
the lack of anxiety-like behaviors when flumazenil was given prior to testing 1 and 2 
days after drug termination.  
 
In addition to changes in behaviors, mice given zolpidem or diazepam treatment 
for 7 days also showed different levels of mRNA expression in the cortex when 
compared to vehicle mice. Both drugs caused decreases in the expression of α1-, α3-, β2-, 
and δ-GABAAR subunits in the cortex. Diazepam treatment also caused decreases in the 
expression α4-, α5-, β1-, and γ2-GABAAR subunits in the cortex. Mice given diazepam 
treatment also showed different levels of mRNA expression in the hippocampus. 
Specifically, these mice displayed lower mRNA expression levels of α5- and γ2-
GABAAR subunits and the NMDA GluN2A subunit. 
 
Study 2 also identified differences in local protein expression. Protein expression 
of total α2 subunit was decreased after zolpidem treatment and protein expression of total 
γ2 subunit was decreased after diazepam treatment in the cortex. The intracellular α1 
subunit protein was decreased after zolpidem treatment, while surface α1 subunit protein 
was unaffected in the cortex. Protein expression of total α1 and α2 subunits in the 
hippocampus were not affected. 
 
 
Study 3: The Effect of 30-Day Zolpidem and Diazepam Treatment on Behavioral 
Sedation and mRNA Expression 
 
 
Tolerance to the Sedative Effects of Zolpidem 
 
The purpose of Study 1 was to examine if a 30-day treatment regimen of 
zolpidem or diazepam induces significant changes to the sedative effects of zolpidem, as 
measured by open field activity, and significant changes in mRNA expression, as 
measured by qRT-PCR. Changes to the sedative effects were examined in Cohort 1 and 2 
mice previously treated with vehicle, diazepam, and zolpidem. A two-way ANOVA on 
found a significant main effect of time, F(5,175) = 196.10, p < 0.01, a significant main 
effect of treatment, F(2,35) = 8.95, p < 0.01, and a significant interaction of Time x 
Treatment, F(10,175) = 2.57, p < 0.01 (Figure 4-26). To examine the interaction, one-
way ANOVAs were performed at each level of time. There were significant group 
differences at Block 1, F(2,54) =4.15, p < 0.05, and Block 2, F(2, 54) =6.57, p < 0.01. 
There were no significant differences at Blocks 3-6, F(2,54) < 4.14, p > 0.05. Follow-up 
Dunnett’s t-tests found that the DZP group displayed more activity than the VEH group 
at Block 1, p < 0.05. At Block 2, both DZP and ZOLP groups exhibited more activity 
than the VEH group, ps < 0.05. 
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Figure 4-26. Decreased locomotor impairing effect of zolpidem after 30-day 
administration of zolpidem, diazepam, or vehicle 
Distance traveled in open field after test administration of 2 mg/kg of ZOLP in mice 
previously given subchronic treatment of ZOLP, DZP, or VEH. Analyses of each 10-min 
block showed that differences between groups were most evident in the first half of the 
60-min test session. Data are presented as mean + sem. Black star denotes VEH< ZOLP 
and DZP groups and Number sign denotes VEH < DZP group (p < 0.05).  
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Changes in mRNA Expression Measured by qRT-PCR 
 
 Cohort 2 mice were used to examine changes in mRNA expression. One-way 
ANOVAs were performed to compare group levels of each mRNA in the cortex, 
hippocampus, PFC, and amygdala. In the cortex, one-way ANOVAs revealed significant 
group differences in mRNA levels of α1 subunits, F(2,35) = 5.18, p < 0.05, and GAT-1, 
F(2,35) = 3.30, p < 0.05. In the hippocampus, ANOVAs revealed significant group 
differences in levels of α4 subunits, F(2,31) = 5.89, p < 0.01, γ2 subunits, F(2,31) = 3.60, 
p < 0.05, and gephyrin, F(2,31) = 4.39, p < 0.05. In the amygdala, a one-way ANOVAs 
revealed significant group differences in mRNA levels of γ2 subunits, F(2,18) = 6.84, p < 
0.01. Follow-up Dunnett’s t-tests performed on all group differences above show that 
DZP or ZOLP groups were not significantly different from the VEH groups, ps > 0.05 
(Figure 4-27). 
 
 In the PFC, one-way ANOVAs found group differences in mRNA levels of 
subunits α1, F(2,30) = 6.67, p < 0.01; α2, F(2,27) = 6.70, p < 0.01; α3, F(2,31) = 5.39, p 
< 0.05; β1, F(2,32) = 4.23, p < 0.05; β2, F(2,32) = 3.75, p < 0.05; β3, F(2,32) = 5.33, p < 
0.05; δ, F(2,32) = 4.16, p < 0.05; γ1, F(2,32) = 5.90, p < 0.01; and γ2, F(2,32) = 4.07, ps 
< 0.05. Follow-up Dunnett’s t-test found significant differences between the VEH and 
ZOLP groups for subunits α1, α2, α3, β1, β2, β3, δ, γ1, and γ2, ps < 0.05. (Figure 4-28). 
 
 In summary, this study indicated that mice given a 30-day treatment of diazepam 
were cross-tolerant to the sedative effects of zolpidem. This study also indicated that 
mice given zolpidem showed some evidence of zolpidem tolerance; however, this effect 
was relatively weak and only observed at time Block 2. There were no significant 
changes in mRNA levels after 30 days of diazepam. However, mice given a 30-day 
zolpidem treatment did significantly decrease the levels of mRNA for GABAAR subunits 
α1, α2, α3, β1, β2, β3, γ1, and γ2 in the PFC. 
 
 
Comparisons of Zolpidem and Diazepam Sedative Effects after 3-, 7-, and 30-Day 
Treatment Durations 
 
Statistical analyses of Studies 1-3 revealed more prominent deficits to the sedative 
effects of zolpidem in mice given zolpidem and diazepam for 7 days in comparison to 3 
days and 30 days. To further inspect these findings, we compared differences in treatment 
duration by drug treatment. To complete this, we first examined whether differences in 
treatment duration (3-, 7-, and 30-days) influenced the distance traveled across the test 
session time (Blocks 1–6) in mice given vehicle treatments (VEH-ZOLP). This 
comparison indicated no significant of time, F(5,240)= 98.09, p < 0.01; duration, 
F(10,240) = 1.35, p > 0.05; or a significant Time x Duration interaction, F(2, 48) = 0.90, 
p > 0.05. These results suggest that the number of injections prior to testing did not 
impact locomotor activity during testing and was not likely a confounding factor 
influencing differences in the sedative effects of zolpidem among studies (Figure 4-29). 
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Figure 4-27. Relative levels of mRNA in the pfc following 30-day administration of 
zolpidem, diazepam, or vehicle 
Histograms comparing levels of transcripts are expressed as mean percentage of VEH 
control (100%). Statistical analyses were performed by ANOVA with Dunnett’s t test for 
pairwise comparisons against a VEH. Data are presented as mean + sem. Ampersand sign 
VEH > ZOLP treatment (p < 0.05).  
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Figure 4-28. Relative levels of mRNA in the cortex, hippocampus, and amygdala 
following 7-day administration of zolpidem, diazepam, or vehicle 
Histograms comparing levels of transcripts are expressed as mean percentage of VEH 
control (100%). Statistical analyses were performed by ANOVA with Dunnett’s t test for 
pairwise comparisons against a VEH. Data are presented as mean + sem. There were no 
significant differences between groups, ps > 0.05.  
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Figure 4-29. No significant differences between vehicle groups from each study on 
motor activity 
Distance traveled in open field after test administration of 2 mg/kg of ZOLP in mice 
previously given subchronic treatment of VEH for 3, 7, or 30 days. Analyses of each 10-
min block showed no differences between. Data are presented as mean + sem. 
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Next, we used the same approach in an attempt to affirm the more prominent 7-
day deficits by separately examining differences in treatment durations of zolpidem and 
diazepam. In mice given diazepam treatments (DZP-ZOLP), the two-way ANOVA 
revealed a main effect of time, F(5,240) = 52.20, p < 0.01. There was no effect of 
duration, F(2,48) = 1.60, p > 0.05 or a significant interaction of Time x Duration,  F(10, 
240) = 1.43, p > 0.05 (Figure 4-30).  
 
In mice given zolpidem treatments (ZOLP-ZOLP), the two-way ANOVA found a 
main effect of time, F(5,295) = 105.08, p < 0.01, duration, F(2,59) = 6.72, p < 0.05, and a 
significant interaction of Time x Duration, F(10,295) =1.92, p < 0.05. To evaluate the 
interaction, one-way ANOVAs were conducted on each block of time. There was a 
significant difference between groups at Block 2, F(2,59) =3.98, p < 0.05, Block 3, 
F(2,59) = 9.18, p < 0.05, and Block 6, F( 2,59) = 3.85, p < 0.05. Mice who received 
zolpidem for 7 days displayed greater activity at Blocks 2, 3, and 6 than mice who 
received zolpidem for 3 or 30 days, p <0.05. There were no significant differences 
between groups at Blocks 1, 4 and 5, Fs(2,59) < 3.10, ps > 0.05 (Figure 4-31). 
 
 
Comparison of Center, and Periphery Distance Traveled: Spontaneous Withdrawal 
 
To assess whether differences in the distance traveled across the test session time 
(Blocks 1–6) influenced measures of open-field anxiety, two-way ANOVAs were 
performed on distance traveled in the center and periphery of the open field. If both 
regions show decreases in activity, then activity would affect interpretation of anxiety-
like measures.  
 
For distance traveled in the center, a two-way ANOVA found that there was a 
main effect of time, F(5,105) = 31.01, p < 0.01, a main effect of treatment, F(2,21) = 
7.21, p < 0.01, and a significant interaction of Time x Duration, F(10,105) = 3.24, p < 
0.01. To assess the interaction, a one-way ANOVAs at each level of time were 
performed. There were group differences at Block 1, F(2,21) = 14.82, p < 0.01, Block 2, 
F(2,21) = 9.09, p < 0.01, Block 3,  F(2,21) = 4.05, p < 0.05, and Block 5, F(2,21) = 3.51, 
p < 0.05. Follow-up Dunett’s t-tests revealed that the activity of ZOLP and DZP groups 
was significantly lower than the VEH groups at Blocks 1 and 2, p < 0.01 and the activity 
of DZP groups was significantly lower than the VEH groups at Blocks 3 and 5, p < 0.05. 
There was no significantly differences at Blocks 4 and 6, Fs (2,21) > 3.17, p > 0.05 
(Figure 4-32). 
 
For distance traveled in the periphery, a two-way ANOVA found that there was a 
main effect of time, F(5,105) = 11.36, p < 0.05, no main effect of treatment, F(2,21) = 
2.03, p > 0.05, and no significant interaction of Time x Duration, F(10,105) = 0.81, p > 
0.05 (Figure 4-33). 
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Figure 4-30.  No significant differences between diazepam groups from each study 
on motor activity. 
Distance traveled in open field after test administration of 2 mg/kg of ZOLP in mice 
previously given subchronic treatment of DZP for 3, 7, or 30 days. Analyses of each 10-
min block showed no differences between. Data are presented as mean + sem. 
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Figure 4-31.  Increased motor activity due to 7 days of ZOLP compared to 3 or 30 
days of ZOLP 
Distance traveled in open field after test administration of 2 mg/kg of ZOLP in mice 
previously given subchronic treatment of ZOLP for 3, 7, or 30 days. Analyses of each 10-
min block showed differences between groups. The 7 day ZOLP group showed greater 
activity than the 3 or 30-day group. Data are presented as mean + sem. 
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Figure 4-32. Decreased motor activity in the center region of the open field 
apparatus 
Distance traveled in open field after administration of VEH in mice previously given 
subchronic treatment of ZOLP, DZP, or VEH. Analyses of each 10-min block showed that 
differences between groups, with the VEH group showing greater activity than the DZP 
or ZOLP groups. Data are presented as mean + sem. Black star denotes VEH< ZOLP and 
DZP groups and Number sign denotes VEH < DZP group (p < 0.05).  
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Figure 4-33.  No significant differences between groups in the peripheral region of 
the open field apparatus on motor activity 
Distance traveled in open field after administration of VEH in mice previously given 
subchronic treatment of ZOLP, DZP, or VEH. Analyses of each 10-min block showed no 
differences between groups, Data are presented as mean + sem. 
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CHAPTER 5.    DISCUSSION* 
 
 
The development of tolerance to the sedative-hypnotic effects of zolpidem and 
symptoms of withdrawal are becoming a growing concern as usage increases in the 
general population [22, 23, 136]. Using mouse models, researchers are discerning what 
factors influence tolerance and withdrawal and the neuromechanisms associated with 
these phenomena [226]. The purpose of our studies were to examine whether 3-, 7-, 
and/or 30-day treatment regimens of zolpidem or diazepam diminished the sedative 
effects of zolpidem in mice. In addition, these studies examined whether treatment 
regimens changed the expression of mRNA and proteins believed to be associated with 
tolerance and withdrawal. 
 
 
Behavioral Tolerance and Cross-Tolerance  
 
Numerous studies have indicated that tolerance to the sedative effects of BZs can 
develop following repeated treatments in rodents; however, there is conflicting evidence 
concerning the development of tolerance to zolpidem [123, 243, 244]. Our finding of 
tolerance after 7 days of zolpidem is in agreement with past studies that show mice 
develop sedative tolerance after 10 days of treatment [25, 105, 123]. However, in Studies 
1 and 3, mice given zolpidem for 3 or 30 days prior to testing show minimal evidence of 
reduced sedation. Past studies examining the development of tolerance to zolpidem’s 
varying effects have primarily examined changes in efficacy or potency after 7-14 days 
of treatment. For example, tolerance to zolpidem’s ataxic, hypothermic, and 
anticonvulsant effects have been observed in rodents and primates during these time 
periods [25, 29, 38, 105, 138]. Other studies have reported no tolerance after zolpidem 
administration in rodents [28, 109]. The detection of zolpidem tolerance in past studies is 
likely influenced by numerous factors, like the time between test injection and behavioral 
testing. One major difference between our and previous studies was the latency between 
our test-drug injection and the onset of tolerance testing. In most studies, the time 
between injections and the start of testing is 15-30 min. Because zolpidem is relatively 
short acting and quickly metabolized, 15-30 min delay between drug injection and testing 
may hamper detection of tolerance. In our studies, the time between the test injection and 
testing was only 2 min. As seen in Figure 4-3, the sedative effects of zolpidem are 
clearly evident during the first 30 min following this test-drug injection and less evident 
during the latter half of the test session.  
 
 
------------------------------------------- 
*Modified with permission. Wright, B.T., Gluszek, C.F. and Heldt, S.A. The effects of repeated 
zolpidem treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile 
expression in mice: comparison with diazepam. Psychopharmacology (Berl), 2014. 231(15): p. 
2967-79. and Fitzgerald, A.C., Wright, B.T., and Heldt, S.A. The behavioral pharmacology of 
zolpidem: evidence for the functional significance of α1-containing GABAA receptors. 
Psychopharmacology (Berl), 2014. 231(9): p. 1865-96 [16, 245].   
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 In contrast to 7 days, 3 and 30 days of zolpidem treatment produced little 
evidence of sedative tolerance in mice. The lack of tolerance after 3 days may be due to 
the fact that sedative tolerance gradually develops and reaches detectable levels only at 
later time points (e.g. 7 days). It is possible that higher treatment dose levels, different 
dose regimens, or higher testing dose levels may result in more apparent detection of 
sedative tolerance. Several experiments can answer this question by increasing the dose 
to > 5 mg/kg or incrementally increasing the dose across time [211]. It is also possible 
that a difference in treatment regime (i.e. subcutaneous or oral treatments) may cause  
tolerance detection at earlier or later time points [123]. This experiment could possibly 
lead to different behavioral manifestations of tolerance. It is unclear if the rates of 
tolerance to zolpidem’s effects develop at differently. 
 
In Studies 1-3, we found repeated diazepam treatments diminished the sedative 
effects of zolpidem, a phenomena termed cross-tolerance. In the case of tolerance, the 
sedative effects of BZs develop before the other effects (e.g. anxiolytic or anticonvulsant) 
[127, 132, 246]. In a recent study, Vinkers et al. showed that mice continually 
administered diazepam for 28 days displayed tolerance to diazepam’s sedative effects as 
well as its hypothermic and anxiolytic effects [112]. While numerous studies have 
documented cross-tolerance between different BZs in rodents, relatively few have 
examined cross-tolerance between zolpidem and BZs [24, 105, 247-249]. The Vinkers 
study also showed that mice given continual zolpidem treatment for 28 days displayed 
cross-tolerance diazepam’s hypothermic and anxiolytic-like effects but not to diazepam’s 
sedative effects [112].  
 
Possible evidence for different mechanisms mediating BZ and zolpidem tolerance 
have been found with experiments using point-mutation mice. These mice have a single 
point mutation in an α-subunit protein, allowing for the receptor to be BZ- and zolpidem-
insensitive. One study found that tolerance to the sedative effects of diazepam in mice 
lacking BZ sensitive α5-GABAARs are greatly reduced [129]. This suggests continual 
activation of α5-GABAARs is an important contributing factor to the development of 
tolerance to diazepam. Zolpidem has very little affinity and efficacy at α5-GABAARs; 
thus, it is unlikely that tolerance to the sedative effects of zolpidem is due to activation of 
α5-GABAARs. This may be indicative of different mechanisms mediating the 
development of sedative tolerance to BZs versus zolpidem 
 
  Together with our results, these findings suggest that chronic BZ treatments can 
cause cross-tolerance to zolpidem’s sedative effects, whereas chronic zolpidem 
treatments are more limited in inducing cross-tolerance to the effects of BZs. In addition, 
this implies that deficits in zolpidem-induced sedative effects are mediated by continued 
allosteric modulation of α1-GABAARs. However, at the doses used in our studies it is 
likely that α2- or α3-GABAARs are activated; thus we cannot exclude the possibility of 
these GABAARs mediating tolerance. Whereas deficits in BZ-induced sedative effects 
may be due to the repeated allosteric activation of other BZ sensitive GABAAR subtypes 
combined with the α1-GABAAR subtype. This may indicate that different GABAAR 
subtypes are associated with BZ and zolpidem sedative tolerance and sedative effects. 
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 In addition to tolerance, is it possible that the sedative effects of BZs and 
zolpidem are mediated by different or a combination of different GABAARs? Another 
question is if tolerance and/or cross-tolerance persists after BZ treatment ends. It has been 
found in human case studies that patients who abuse zolpidem had previous 
benzodiazepine abuse as well [26]. This may be indicative of permanent changes in 
GABAARs functioning and it would be valuable to see if rodents exhibit sedative 
tolerance after drug cessation. 
 
 
Behavioral Withdrawal 
 
 In humans, the abrupt cessation of prolonged BZ treatments can be followed by 
unpleasant withdrawal symptoms, which are believed to play a role in BZ abuse and 
dependence [4, 250]. The abrupt cessation of supratherapeutic doses of zolpidem can also 
lead to a BZ-like withdrawal syndrome [139, 147, 251-254]. In nonhuman primates and 
rodents, repeated BZ administration also produces physical dependence, detected by 
spontaneous and flumazenil-induced withdrawal symptoms [6, 255-258]. In nonhuman 
primates, these withdrawal effects are also observed after repeated treatment with 
zolpidem [133, 150]. Withdrawal-like symptoms are less likely observed in rodents after 
zolpidem discontinuation in comparison to diazepam [24, 28, 38, 152, 259-261]. The 
distinctive pharmacological profile observed in rodents and primates may be explained 
by differences in the distribution of α1-GABAAR subtypes and/or the binding 
characteristics of zolpidem. In vitro autoradiography experiments reveal substantial 
differences in [3H]zolpidem binding in the brains of rats and humans [76]. These 
differences in the binding characteristics of specific brain regions may likely contribute to 
the distinctive pharmacological effects of zolpidem in rodents and primates. 
 
In our study zolpidem and diazepam treated mice given vehicle prior to testing 
showed spontaneous withdrawal. These mice displayed anxiety-like with decreases in 
activity, frequency of rearing, and center entries. There were also progressive decreases 
in percent time spent in the center zone, indicative of increasing anxiety during testing. 
The display of anxiety-like behavior from spontaneous withdrawal in our study are in line 
with rodent studies that have identified anxiety-like behavior in zolpidem treated mice 
after spontaneous withdrawal [28, 259, 260]. Our results are also consistent with previous 
studies showing anxiety-like behaviors in the elevated plus maze, open field, and social 
interaction test when assessed 1-3 days after prolonged diazepam treatments [101, 227, 
228, 246, 255, 262]. Though both groups of mice displayed anxiety-like behavior in the 
open field, they also showed reduced locomotion. Unlike our findings, hyper-locomotion, 
a typical symptom of spontaneous withdrawal, is detected after abrupt cessation of 
diazepam [125]. Possible that testing could produce anxiety-like behaviors concomitant 
with hyper-locomotion at later time points. 
 
While it is possible that the decreases in activity were associated with the residual 
drug effects during testing, evidence from previous studies suggest this is not the case. In 
rats, the t1/2 from plasma is approximately 30 min for zolpidem and 70 min for diazepam 
and its active main metabolite desmethyldiazepam [33, 34, 37, 263-265]. In the case of 
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zolpidem, daily injections do not change t1/2 values or result in accumulation in plasma or 
the brain [35]. Repeated injection of zolpidem for up to 28 days is virtually undetectable 
3–4 h after the last injection, and the degradation of zolpidem does not lead to the 
formation of metabolites that can accumulate and sustain drug action [31, 35, 266]. Daily 
diazepam injections do not change t1/2 values and most studies but not all reveal no 
plasma accumulation of diazepam or its metabolite after long-term treatment [124, 233, 
265, 267, 268]. These data argue against dramatic changes in the pharmacokinetics as the 
basis for the detection of withdrawal. 
 
In contrast to spontaneous withdrawal, Study 2 showed that zolpidem and 
diazepam treated mice given flumazenil after treatments displayed minimal flumazenil-
induced withdrawal, as measured by anxiety-like behavior. The lack of flumazenil-
induced withdrawal in diazepam treated mice is contrary to studies that have found that 
flumazenil treatment results in anxiety-like behavior and hyper-locomotion [51-53]. Our 
study is in line with another study that did not find anxiety-like behavior in zolpidem 
treated mice given flumazenil [38].  
 
Study 2 found that spontaneous withdrawal results in anxiety-like behavior and 
hypo-locomotion. Both spontaneous and flumazenil induced withdrawal can induce other 
withdrawal symptoms like handling induced convulsions that could be detected. A 
possible experiment would be to see if cessation of drug can cause handling induced 
convulsions could be detected after 3, 7, or 30 days of zolpidem or diazepam, as noted by 
past studies [269]. In addition, examining spontaneous withdrawal at time points beyond 
one day may provide information about the duration and severity of withdrawal 
symptoms. While withdrawal can be observed hours after drug discontinuation, some 
studies have found that BZ withdrawal may not occur until up to 3 days after drug 
treatment has stopped. If the spontaneous withdrawal experiment conducted had tested 
withdrawal days later, there may have been hyper-locomotion. Study 2 focused on 
anxiety-like behavior and locomotor activity due to flumazenil-induced withdrawal but 
are there other withdrawal symptoms or tests that could occur like convulsions and since 
flumazenil resulted in minimal effects is it possible that other drugs like PTZ can better 
induce withdrawal symptoms [25, 200, 269]. 
 
It is hypothesized that zolpidem withdrawal and tolerance are due to long-term 
supratherapeutic dose activation of the α2- and α3-GABAARs along with α1-GABAARs 
[175]. While zolpidem binds to α1-subunits with an affinity that is five- to ten-fold 
greater than α2- and α3-GABAARs, in vitro studies show the relatively high dose of 
zolpidem used in this study might be sufficient to activate these lower-affinity GABAARs 
in vivo and contribute to deficits in the locomotor-impairing effects of zolpidem and 
anxiety-like behaviors [17, 270].  
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mRNA and Protein Expression 
 
 
GABAAR Subunits mRNA and Protein 
 
Repeated BZ administration produces numerous neuroadaptive changes in 
specific brain regions; however, it is unknown which neuroadaptive factors predict 
whether a certain BZ possesses the potential to produce tolerance. In our studies, we 
chose to examine mRNA changes in the cortex, hippocampus, amygdala, and PFC due to 
their involvement in the control of locomotor activity, sedation, and withdrawal 
symptoms as well as documented mRNA alterations that occur due to BZs and zolpidem 
[111, 113, 187, 234]. Many studies suggest changes in GABAAR subunit mRNA 
contribute to tolerance and withdrawal after long-term BZ treatment regimens [92, 106, 
108, 111, 113, 271, 272].  
 
In agreement with Study 2, most data suggest repeated diazepam treatments alter 
α1-subunit mRNA expression in the cerebral cortex, although this is not observed in all 
studies [105-113]. Other studies have shown that diazepam treatment decreases α1-
subunit mRNA in the hippocampus and prefrontal cortex [105, 107]. Also diazepam 
treated mice showed a decrease in α4, β1, and γ2 subunits in the cortex and α5-, γ2-
GABAAR subunits, and GluN2A subunits in the hippocampus. This latter finding is 
consistent with some reports that find decreases in mRNA expression of α5 subunits 
[107, 113, 116]. Some studies find that repeated diazepam treatment (> 7 days) induced 
significant increases in α3, α4, α5, β1, and γ3 subunits as well as decreases in β2 and γ2 
subunits [107, 273]. Others find long term diazepam caused an increase in the α1-subunit 
mRNA expression in the parietal cortex and ventral pallidum but no change in α1 or γ2 in 
the other areas [273]. Study 2 observed cortical decreases in α3- and δ-subunit mRNA 
after both treatments and α4-subunit mRNA after diazepam treatment. It has been found 
that long-term treatment with diazepam increased α3 and α4 mRNA expression in the 
cerebral cortex, whereas other studies have found no such effects [107, 111, 115, 116]. 
 
In mice treated with zolpidem for 3 days, we observed a decrease in the mRNA 
expression of the α5 subunit in the hippocampus and in mice treated with zolpidem for 30 
days showed a decrease in the mRNA expression of α1, α2, α3, β1, β2, β3, γ1, and γ2 
subunits in the PFC. We observed that zolpidem treated mice showed a decrease in α1, 
α3, β2, and δ subunits in the cortex. We also found that an acute dose of either drug did 
not affect mRNA levels (Appendix). One of the most consistent finding is that long-term 
zolpidem treatment decreases α1 mRNA in cerebral cortex after 14 days of treatment in 
rats [234]. An upregulation of α4 mRNA in the cortex has also been identified after long-
term treatment with zolpidem [234]. No previous studies have noted changes in δ mRNA 
after long-term zolpidem exposure in vivo [107, 234].  
 
It must be noted that many studies have shown inconsistent findings that limit the 
essential or key changes underlying tolerance and withdrawal. Also of note is that rats 
have been historically used to investigate mRNA changes associated with tolerance and 
withdrawal after BZ treatments, while mice have been used in only a few studies [271, 
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272]. Neuroanatomical and behavioral differences between these two species may 
contribute to published discrepancies [274-276]. Other inconsistencies are due to 
differences between treatment regimen and subanatomical regions. For example some 
studies used infusions pumps or s.c. injections [115]. Others look at specific regions like 
the CA1 region of the hippocampus, frontoparietal motor cortex, or frontoparietal 
somatosensory cortex [107, 112]. 
 
Both α4- and δ-GABAARs are usually found in perisynaptic and extrasynaptic 
regions of the brain, including the cortex [277, 278]. These receptors are insensitive to 
BZs and zolpidem, indicating that changes in GABAAR mRNA levels are not necessarily 
dependent on direct drug-receptor interaction. In cultured cells, withdrawal from repeated 
treatment of diazepam and zolpidem has been shown to increase α4-subunit mRNA and 
decrease α1-subunit mRNA, suggesting that the molecular events that underlie 
withdrawal may involve a shift from BZ-sensitive to BZ-insensitive GABAAR subtypes 
[188, 189]. While zolpidem preferentially binds to α1-GABAARs, it also possesses some 
agonistic action on α3-GABAARs at high doses which may mediate the decrease in α3 
mRNA after zolpidem treatment [17, 279]. It is noteworthy that the anxiolytic effects of 
BZs are putatively mediated by α2- and α3-GABAARs [99, 280, 281]. While no mRNA 
changes were detected in the amygdala, which is known to be involved in fear and 
anxiety, changes in the function of these receptors in the cortex may play a role in the 
processing of sensory information that mediate anxiety-like behavior seen in diazepam 
and zolpidem groups treated with vehicle in Study 2 [232]. 
 
Due to the development of cross-tolerance in diazepam treated mice to zolpidem 
and the lack of tolerance in zolpidem treated mice in Study 1 and 3, it was expected that 
the diazepam treated mice would show changes in mRNA expression. Vinkers 2012, 
found that 28 days of diazepam resulted in an increase in the α2 subunit in the 
hippocampus (CA1 region) [112]. Though this study showed mRNA changes in the α2 
subunit in the hippocampus, like our study it did not show any changes in the cortex or in 
the hippocampus with α1 or α5 subunit. It has been shown that the mRNA expression of 
the α4 subunit increases during tolerance and during withdrawal from diazepam and 
zolpidem [115, 234]. In the present study we did not see a similar increase in either 
group. 
 
One would expect since BZs like diazepam have similar affinity and efficacy to 
multiple GABAARs, that changes in mRNA transcripts would be more pronounced and 
frequent than zolpidem. This may be the reason we saw more pronounced alterations due 
to diazepam versus zolpidem in Study 2. An expectation is that zolpidem would only 
alter α1 subunits because it primarily binds to α1-GABAARs. As our study and other 
studies have found repeated zolpidem does have more broad effects on other GABAergic 
transcripts. Studies 1-3 focused on measuring the mRNA expression of GABAARs 
subunits. Is it possible that other non-GABAergic changes occurred after 3 or 30 days of 
zolpidem or diazepam? Future experiments should examine if changes in non-
GABAergic (eg. NMDAR or AMPAR subunit mRNA) occur after these time points in 
zolpidem or diazepam groups. Another unexamined question is the temporal duration of 
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identified mRNA changes in this study. Experiments looking at mRNA changes greater 
or less than 1 day after drug cessation might identify acute or more long term changes. 
 
Examination of selective GABA subunits at the protein level indicated mice given 
zolpidem had decreased expression of total α2 protein in the cortex and mice given 
diazepam had decreased expression of total γ2 protein and decreased intracellular α1 
protein in the cortex. Mice given prior zolpidem or diazepam did not show any changes 
in the cortex of total α1, α3, NR1, NR2A, or surface α1 protein expression. There were 
also no changes in the hippocampus of mice given prior zolpidem or diazepam of total α1 
or α2 protein expression. Most in vivo studies of repeated BZ treatment show a decrease 
in α1 and increases in α5, β2, and γ2 protein [107, 109]. We found a decrease in γ2 
protein but no changes in α1 protein expression. In vitro studies of long-term diazepam 
treatment on rat cerebellar neurons found diazepam treatment decreased α1 and γ2 
protein expression during treatment and after withdrawal increased α4 protein expression 
[189, 254]. 
 
Some studies observed decreased number of BZ binding sites after long-term BZ 
treatment [244]. Receptor uncoupling, internalization, and degradation of GABAAR 
subunits have been proposed as mechanisms underlying BZ tolerance [151, 197, 282, 
283]. While these mechanisms are not fully understood, posttranslational processes, such 
as phosphorylation, are likely to play key roles [284, 285]. Other studies have 
demonstrated that altered mRNA levels induced by chronic BZ exposure can correlate to 
their respective protein levels in vivo [107, 109]. Thus, it is conceivable that mRNA 
changes seen in this study coincide with changes in the expression of their respective 
proteins. However, the relationship between changes in mRNA levels and corresponding 
protein level is not well characterized. While mRNA serves as an intermediate between 
DNA and protein, they are subject to posttranscriptional processing by RNA-binding 
proteins that bind to multiple sites on numerous RNAs to function in diverse time- 
dependent processes [286]. 
 
 It has been hypothesized that due to zolpidem binding preferentially to α1-
GABAARs that tolerance would be associated with decreases in α1 and γ2 protein 
expression [105]. We also expected to see a decrease in surface expression of α1 subunit 
for the same reason. It is possible that the high variability and the failure to see statistical 
significance with our mRNA and protein experiments were due to small sample sizes. 
Some of the experiments only had 3-6 mice per group, leading to high variability which 
may have masked significant results. Future experiments with increased sample size may 
reduce variability and identify significant differences. 
 
 Our study only looked at protein expression after 7 days of drug treatment, 
however it is possible that changes in protein occur earlier or later. Experiments should 
be conducted at 3 or 30 days of drug treatment. The study focused on the changes of 
select GABAAR and NMDAR subunits and it may be possible that changes occur at other 
signaling transcripts or proteins like KCC2, mGlu5, or PKC [204, 211]. Since there was a 
decrease in α2 subunit expression after zolpidem treatment, the use of the α2 point 
mutation mice might show if α2-GABAARs affect zolpidem sedative tolerance. A single 
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high dose of diazepam (30 mg/kg) given to wild-type mice can also produce brain-
region-dependent reduction in the expression level of mRNA transcripts involved in the 
regulation of synaptic plasticity such as c-Fos, CaMKII, and BDNF [287]. Interestingly, 
many of the transcript changes induced by diazepam in wild-type mice are not altered in 
mice with α1-GABAARs that have been rendered diazepam-insensitive by point 
mutations, indicating that these transcript changes are specifically mediated by α1- 
containing GABAARs. 
 
 
NMDA 
 
Repeated BZ treatment also affects ionotropic glutamate receptor subunit gene 
expression. As reviewed elsewhere, alterations in other neurotransmitter systems have 
been implicated as neuroadaptive mechanisms underlying the development of tolerance 
and withdrawal to BZ-like drugs, including an upregulation of the glutamatergic system 
[151, 288]. In Study 2 it was found that only diazepam treated mice showed a decrease of 
the mRNA expression of GluR2A subunit mRNA in the hippocampus. There were no 
other group differences in the hippocampus of GluR1, GluR2B, GluN1 or GluN2 mRNA 
levels. There were also no group differences for any of the NMDA or AMPA subunit 
mRNA levels in the cortex, amygdala, or PFC. Our results differ from other studies that 
find increases in GluR1 and GluR2B, but no increase in GluR2A mRNA levels in the 
hippocampus after diazepam treatment [118, 119]. Increases in the expression of AMPA 
receptor subunit mRNAs and AMPA receptor ligand binding have been reported in a 
number of brain areas after BZ withdrawal [53, 289]. We expected that Study 2 would 
identify increases in GluR1 and GluR2B mRNA, as found in other studies looking at 
repeated diazepam in mice [118, 119]. One difference between our study and others is the 
time point of sacrifice after drug termination. Our study waited 16-20 hours after last 
injection whereas others have waited as long as 96 hours after drug termination. Another 
difference is the method of mRNA analysis. The duration of treatment between Study 2 
and past examinations differed. In our study treatment lasted 7 days as opposed to 3 or 14 
days [117, 119]. We used qRT-PCR as opposed to in situ hybridization.  
 
Because other studies have noted changes in NMDAR and AMPAR subunits at 
varying time points, it is possible that changes in these subunit mRNA may have 
occurred at 3 or 30 days of treatment. Also is it possible that these changes would only 
occur during withdrawal. This study focused on ionotropic glutamate receptors but is it 
possible that our repeated zolpidem and diazepam could result in changes in metabotropic 
glutamate receptors. One study has found that repeated zolpidem treatment can increase 
mGluR5 protein [204]. There is evidence that mGlur5 interacts with α1-GABAARs [205].  
 
At the protein level, zolpidem- and diazepam-treated mice did not show any 
changes in the cortical GluR1 and GluR2 subunits. This is in contrast to other studies that 
found increases in GluR1 but not GluR2A protein expression [117]. Electrophysiological 
data indicate that a single in vivo dose of zolpidem or diazepam can produce an increase 
in the AMPA/NMDA current ratio and activity of mesolimbic dopamine neurons [167]. 
Gene-targeted mice lacking the GluR1 subunit of AMPARs show less tolerance to a 
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number of the acute behavioral effects of flurazepam (e.g., loss of righting reflex, 
walking beam impairments) after high-dose treatments [121, 290]. In contrast, greater 
flumazenil-induced withdrawal-like symptoms are seen after treatment termination. 
Together, these findings suggesting alterations in AMPA receptors are involved in 
mediating the processes involved in BZ tolerance and withdrawal. 
 
 A variable to consider is the small sample sizes of Studies 1 and 3 which may 
have resulted in high variation in our data sets. The small sample sizes of our data sets 
may have masked a possible significant result. Therefore future experiments should have 
a greater number of mice per group to address this problem. This project focused on 
mRNA alterations of GABAAR subunits and associated proteins in Studies 1-3 and Study 
2 also focused on alterations of NMDA and AMPA receptor subunits. As mentioned 
above, the focus of this study may have missed other mRNA and protein alterations like 
those of mGluR, KCC2, PKA, and PKC, that have been found to be associated with BZ 
and zolpidem tolerance and are known to interact with GABAARs [204, 205, 209, 211]. 
 
 
Connection Between Sedation, Withdrawal, and Observed Alterations in the mRNA 
and Protein Levels in the Cortex, PFC, Hippocampus, and Amygdala  
 
Our results, similar to past studies, found tolerance and cross-tolerance to 
zolpidem after 7 days of repeated zolpidem and diazepam treatments. We also found that 
an abrupt end of treatment caused withdrawal anxiety and a reduction in motor activity, a 
measure of sedation. The most significant changes in mRNA and protein expression 
occurred during this treatment duration. The cortex and the hippocampus were the only 
regions that had decreased expression of GABAAR subunits and NMDAR subunits. Both 
zolpidem and diazepam groups had decreased mRNA levels of α1-, α3-, β2-, and δ-
GABAAR subunits in the cortex. The decreases in α1, α3, and β2 are in line with other 
studies, but the decrease in cortical δ mRNA levels has not been previously documented 
in the cortex or other brain regions. Past studies hypothesize decreases of α1, α3, and β2 
may be indicative of a decrease in GABAARs in the cortex. A decrease in these subunits 
may result in a decrease in efficacy of diazepam and zolpidem in the cortex and 
contribute to our measure of behavioral tolerance observed in the study. The decrease of 
the δ-subunit mRNA has not been seen in other studies. This finding is surprising given 
that neither zolpidem nor diazepam bind to GABAARs that contain the δ subunit. Because 
the location of δ-subunits in the cortex is not firmly established, it is unclear how this 
affects the development of tolerance. However δ-subunits are known to be incorporated 
in extrasynaptic GABAARs that mediate tonic inhibition, thus reduction may cause an 
overall decrease in baseline tonic inhibition resulting in an increase in excitatory tone. 
  
The diazepam group had decreased mRNA levels of α4-, β1-, γ2-subunits, GAT, 
and gephyrin in the cortex. In addition this group showed significant decreases of α5- and 
β3-GABAAR subunits and GluN2A subunit in the hippocampus. A decrease in the 
mRNA of the γ2-subunit and gephyrin in the cortex due to repeated diazepam may 
indicate decrease in BZ-sensitive GABAARs, as the γ2-subunit is necessary for BZ 
binding and gephyrin plays a role in maintaining GABAARs on the cell surface. It is 
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unclear how a decrease in GAT-1 influences tolerance, because a decrease in GAT-1 
should lead to a greater concentration of GABA in the synaptic cleft and increased 
inhibition. It is also unclear why there was a decrease in α4 or β1 mRNA levels because 
diazepam nor zolpidem bind to GABAARs with these subunits, although a decrease in α4-
subunit could result in a decrease in GABAARs responsible for tonic inhibition. Other 
studies tend to see an increase in α4 mRNA levels, which could result in an increase in 
BZ- and zolpidem-insensitive GABAARs. 
 
 At the protein level our findings did not completely correspond with changes in 
mRNA levels. Future studies with more refined and sophisticated experimental designs 
may help resolve discrepancies between mRNA and protein levels seen in our studies. 
Although some of our results are unresolved, they generally confirm that modulation of 
neocortical circuits by changes in GABAARs play a role in the motor impairing effects of 
PAMs and eventual development of tolerance to zolpidem and diazepam [103].  
 
The diazepam groups had a decrease of α5- and β3-GABAAR subunits, and the 
GluN2A subunit in the hippocampus. The decrease of α5 is in line with other studies that 
examine the effects of repeated diazepam in the hippocampus as diazepam binds to 
GABAARs with this subunit. It is unlikely that a decrease in either of these GABAAR 
subunits influence sedative cross-tolerance to zolpidem, because α5-GABAARs do not 
participate in the sedative effect of zolpidem. Alterations in α5-GABAARs could, 
however, alter memory functions, because hippocampal α5-GABAARs are known to be 
involved in memory and learning. The decrease in GluN2A mRNA levels are novel, 
though it is unclear how it affects sedative tolerance. Past studies have reported that 
changes in GluN1 and GluN2B but not GluN2A mRNA and protein levels are associated 
with the contextual dependent features of PAM tolerance [118, 119, 249]. Because 
GluN2A is involved in learning in memory, these changes may be associated with 
contextual dependent features.  
 
Three days of repeated zolpidem did not produce sedative tolerance but did result 
in a decrease in α5 subunit mRNA levels in the hippocampus. These results only partially 
supported our hypothesis. As stated above, it is known that changes in hippocampal α5-
GABAARs do not influence the sedative effects of zolpidem. It is possible that the 
decrease in α5 subunits is a compensatory change or associated with neuroadaptive 
changes unrelated to sedation. Although this project found cross-tolerance to zolpidem 
occurs after 3 days, there were no corresponding changes in mRNA levels. Past studies 
have found that there are alterations in GluN1 and GluN2B after 4 days [118, 119]. Thus 
mechanisms associated sedative cross-tolerance after short-term durations may not be 
associated with measurable GABAergic alterations.  
 
Thirty days of repeated zolpidem did not produce sedative tolerance but did result 
in molecular alterations. These results only partially supported our hypothesis. Although 
30 days of zolpidem did not result in sedative tolerance, our findings do not rule out the 
development of withdrawal symptoms afterwards. Thirty days of repeated zolpidem did 
result in the decrease of α1-, α2-, α3-, β1-, β2-, β3-, γ1-, and γ2-subunit mRNA levels in 
the PFC. PFC glutamatergic projections to the amygdala strongly inhibit the amygdala; 
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thus, the loss of prefrontal inhibition may increase the glutamatergic drive to the 
amygdala which can increase anxiety associated with withdrawal symptoms [100]. 
Although this project found cross-tolerance to zolpidem occurs after 30 days, there were 
no corresponding changes in GABAergic mRNA levels. Vinkers et al. (2012), have 
shown that 28 days of diazepam treatment resulted in sedative tolerance to diazepam but 
no detectable cortical GABAergic mRNA changes and few hippocampal changes [112]. 
Thus, the presence of sedative tolerance after long term PAM treatments are not always 
dependent on observable GABAergic alterations. 
 
 
Limitations 
 
 Our studies provide insight into possible mechanisms behind zolpidem tolerance, 
although there are limitations to our interpretations. Protein expression was not looked at 
in all studies. Though GABAAR mRNA and protein expression have been shown to 
correlate with each other that may not be the case here [107, 109]. We found in Study 1 
and 3 that changes in mRNA expression were not associated with the development of 
cross-tolerance. The diazepam groups in both studies showed cross-tolerance but no 
changes in mRNA expression, and the zolpidem group in both studies showed no 
tolerance and minimal changes in mRNA expression. Studies 1 and 3 measured tolerance 
and mRNA expression in the same mouse whereas Study 2 did not. This would have 
allowed for correlations on distance and mRNA expression. If prominent changes 
behavioral and mRNA changes were identified in the same animal in Study 2 correlations 
may have identified a more definitive relationship between behavioral and neuroadaptive 
changes. In addition to GABAergic alterations, changes in other neurotransmitter systems 
and proteins could be involved in zolpidem and diazepam tolerance, but were not 
investigated in our studies which focused on GABAAR subunits and to a lesser extent 
AMPAR and NMDAR subunits.  
 
 
Conclusions 
 
In summary, this project found that 3 and 30-day zolpidem use did not result in 
tolerance to zolpidem’s sedative effects whereas diazepam treatment at all treatment 
durations produced cross-tolerance. Three and 30 day treatments of zolpidem but not 
diazepam resulted in minimal GABAergic mRNA changes. Though there were minor 
changes in mRNA expression in the PFC with 30-day zolpidem and minor changes in the 
hippocampus after 3 day zolpidem, these changes are likely independent from sedative 
tolerance. Seven-day zolpidem and diazepam administration can produce acute deficits in 
the locomotor-impairing effects of zolpidem and anxiety-like behaviors upon drug 
termination (spontaneous withdrawal) but not precipitated withdrawal. Our results 
demonstrated that zolpidem and diazepam treatments have differing effects on GABAAR 
subunit mRNA expression, mainly in the cortex, which may partially contribute to 
mechanisms underlying the behavioral phenomena. In general, repeated zolpidem 
produced fewer changes in the efficacy in of zolpidem in comparison to repeated 
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diazepam. However, continued research into tolerance and withdrawal to zolpidem are 
necessary due to the growing abuse of zolpidem. 
 
 
Clinical Significance and Implications of Research  
 
This project showed that 7 days of repeated zolpidem and diazepam resulted in 
the emergence of sedative tolerance and withdrawal. Along with sedative tolerance, there 
were significant changes, primarily in the cortex, of GABAergic mRNA and protein 
levels associated with BZ and zolpidem functioning. Our research indicates the cortical 
alterations may play a major role in the development of tolerance to zolpidem, similar to 
what other studies have found. Cortical GABAARs appear to be mediate tolerance and the 
development of future sedative-hypnotics should focus on creating drugs that are either 
GABAAR subtype selective or drugs that work directly on the arousal system. Subtype 
selective PAMs that only bind to α1-GABAARs with little or no affinity or efficacy to 
other GABAAR subtypes may prevent the development of sedative tolerance and 
withdrawal. Recently developed orexin receptor antagonists (Suvorexant) that target 
arousal regions like the locus coeruleus, TMN, and raphe nucleus have been developed 
and marketed as alternatives to currently used PAMs. Early results suggests orexin 
antagonists show reduced propensity of typical BZ and zolpidem side effects, like 
dependence, suggesting they are safer than hypnotic PAMs. Comparing zolpidem to 
orexin antagonists or other α1-GABAAR selective PAMs may help us better understand 
the relationship between molecular alterations and the development of tolerance and 
withdrawal in humans and better aid in the development of treatment options for the 
treatment of insomnia. 
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APPENDIX.  MRNA EXPRESSION AFTER 1 DAY OF VEH, DZP, AND ZOLP 
 
 
Region Vehicle Zolpidem Diazepam 
Cortex Mean SEM Mean SEM Mean SEM 
α1 1.00 0.04 1.01 0.06 0.99 0.05 
α2 1.00 0.08 1.02 0.09 1.08 0.07 
α3 1.00 0.10 1.02 0.08 1.02 0.09 
α5 1.00 0.07 1.00 0.09 1.02 0.08 
β2 1.00 0.09 0.92 0.06 0.87 0.08 
γ2 1.00 0.09 1.01 0.03 0.95 0.05 
GAT-1 1.00 0.06 0.97 0.07 0.94 0.08 
Hippocampus Mean SEM Mean SEM Mean SEM 
α1 1.00 0.19 1.31 0.22 1.40 0.17 
α2 1.00 0.12 0.94 0.15 1.08 0.11 
α3 1.00 0.30 0.80 0.07 0.84 0.22 
α5 1.00 0.27 1.41 0.17 1.49 0.28 
β2 1.00 0.16 1.22 0.14 1.15 0.18 
γ2 1.00 0.10 1.01 0.13 1.01 0.05 
GAT-1 1.00 0.22 0.65 0.10 0.76 0.05 
Amygdala Mean SEM Mean SEM Mean SEM 
α1 1.00 0.08 1.12 0.10 1.21 0.05 
α2 1.00 0.14 1.23 0.21 1.34 0.10 
α3 1.00 0.21 1.43 0.15 1.41 0.09 
α5 1.00 0.34 0.75 0.09 0.94 0.13 
β2 1.00 0.11 1.01 0.12 1.07 0.06 
γ2 1.00 0.06 1.05 0.11 1.10 0.03 
GAT-1 1.00 0.08 0.90 0.09 1.16 0.06 
Amygdala Mean SEM Mean SEM Mean SEM 
α1 1.00 0.10 0.85 0.23 0.77 0.02 
α2 1.00 0.07 0.94 0.27 0.83 0.06 
α3 1.00 0.14 0.70 0.36 0.32 0.14 
α5 1.00 0.17 1.28 0.10 1.79 0.28 
β2 1.00 0.08 0.84 0.29 0.62 0.06 
γ2 1.00 0.07 0.90 0.19 0.78 0.02 
GAT-1 1.00 0.11 0.85 0.25 0.64 0.09 
 
There were no differences in mRNA expression after 1 day of zolpidem or diazepam. 
mRNA levels expressed as proportion of VEH controls. Modified with permission. 
Wright, B.T., C.F. Gluszek, and S.A. Heldt, The effects of repeated zolpidem treatment on 
tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile expression in 
mice: comparison with diazepam. Psychopharmacology (Berl), 2014. 231(15): p. 2967-
79.  
  
109 
VITA 
 
 
 Brittany T. Wright was born in Spartanburg, South Carolina, in 1988. She 
attended Clemson University where she earned a Bachelor’s of Science in Psychology on 
May 2010 and will be receiving her Ph.D. in Biomedical Sciences with a concentration in 
Neuroscience from the University of Tennessee Health Science Center in August of 
2016. 
 
 
 
 
